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Basic and clinical research suggests the loss of estradiol following menopause may 
contribute to accelerated brain aging and the increased risk of age-related cognitive decline and 
dementia. Novel estrogenic compounds may confer positive cognitive effects without the added 
risk of side effects associated with current agents. G-1 is a recently developed agonist for the 
novel transmembrane estrogen receptor (ER) GPR30. Activation of the GPR30 pathway is 
independent of either the classical ER  or  pathways, raising the possibility of using G-1 as a 
novel estrogenic agent while avoiding the risks associated with other estrogenic compounds. 
Previous work in our laboratory has shown that estradiol enhances cognitive performance via 
effects on basal forebrain cholinergic neurons. We hypothesize the effects of estradiol on 
cholinergic function and cognitive performance are mediated by GPR30. If correct, then 
selective GPR30 agonists may provide useful alternatives to current estrogenic therapies. To test 
this hypothesis the first goal was to characterize GPR30 expression in the rat forebrain, focusing 
on co-expression by cholinergic neurons. A RT-PCR assay was developed to quantify GPR30 
mRNA in specific brain regions. GPR30 protein and mRNA expression were found in regions of 
the brain important for spatial learning and memory. Moreover, GPR30 protein appears to be 
expressed by the vast majority of cholinergic neurons. The second goal was to examine the 
effects of GPR30 activation on cholinergic neurons. In vivo microdialysis and HPLC analysis of 
acetylcholine levels in dialysates were used to compare effects on acetylcholine release. 
Administration of a GPR30 agonist or estradiol (E2) to ovariectomized (OVX) rats produced a 3-
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fold increase in potassium-stimulated acetylcholine release in the hippocampus relative to 
vehicle-treated controls. The third goal was to test the ability of GPR30 agonists and antagonists 
to enhance or impair cognitive performance in rats. GPR30 agonism enhanced the rate of 
acquisition on a delayed matching-to-position (DMP) T-maze task in OVX rats similar to 
estradiol while GPR30 antagonism dose-dependently impaired performance in gonadally intact 
and OVX+E2 rodents. Hence, GPR30 appears to play an important role in mediating direct 
effects of estradiol on basal forebrain cholinergic neurons, with corresponding effects on 
cognitive performance.  
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I. INTRODUCTION 
IA. Estrogen Effects on Cognition 
Over the past few decades, we have seen vast improvements in medical technology and 
research that have resulted in better health care and increasing lifespan. In fact, in 1900 the life 
expectancy of a female was 54 years, whereas today the average is 83 years in industrialized 
countries (Singh, 1996). Since the age to menopause has not changed, and women are spending a 
longer portion of their lives in the post-menopausal years, increased efforts have been made to 
discover new ways to prevent and treat neurodegenerative diseases. Much of this work has 
focused on estrogens and the potential benefits it may have on cognitive function.  
Animal studies show that estrogens have many beneficial effects on the brain, such as 
reducing neuronal loss following cardiac arrest and stroke (Suzuki et al., 2006), increasing 
neuronal connectivity (Spencer et al., 2008), improving cognitive performance (Daniel, 2006), 
and preventing or slowing age-related cognitive decline (Frick, 2009; Gibbs and Gabor, 2003). 
Young adult ovariectomized (OVX) rodents that are treated with estradiol (E2) perform better on 
learning and memory tasks such as T-maze and radial arm maze tasks (Daniel et al., 1997; 
Gibbs, 1999), place and object recognition tasks (Fernandez et al., 2008; Frye et al., 2007; 
Gresack and Frick, 2006a), and contextual or cued fear conditioning (Jasnow et al., 2006), than 
OVX controls. These task-effects are selective and can vary depending on the type of memory 
tested (Davis et al., 2005; Fader et al., 1999; Galea et al., 2001; Korol and Kolo, 2002), level of 
hormone (Wide et al., 2004), and prior stress (Wood and Shors, 1998). Human studies likewise 
show beneficial effects of estrogens on specific cognitive tasks in younger surgically menopausal 
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or perimenopausal women, particularly in the realm of verbal memory and executive functioning 
(Sherwin and Henry, 2008). Several studies have reported estrogen-mediated increases in 
cerebral blood flow (Greene, 2000; Resnick and Maki, 2001), and reductions in hippocampal and 
cortical atrophy associated with aging and Alzheimer’s disease (AD) (Erickson et al., 2007; Hu 
et al., 2006), as well as significant reductions in memory decline (Resnick et al., 1997) and in the 
risk of developing Alzheimer’s disease (AD)-related dementia (Figure 1) (Henderson, 2009; 
Zandi et al., 2002). A recent study also reported that women who experience an early menopause 
are at significantly greater risk for age-related cognitive decline and dementia, and that this risk 
is mitigated by early estrogen therapy (Shuster et al., 2010). 
 
Figure 1. Risk of developing Alzheimer’s Disease in men and women over time (A) and in 
women who have been placed hormone replacement therapy (HRT) for varying amounts of time. 
Graphs from(Henderson, 2009; Zandi et al., 2002). 
Despite these encouraging findings, recent randomized trials suggest far fewer benefits 
when estrogen therapy is initiated in older women. In fact, several large trials have reported 
either no beneficial effect or increased harm for women receiving hormone therapy (HT) in old 
age (Resnick et al., 2006; Shumaker et al., 2003; Shumaker et al., 2004). The Women’s Health 
Initiative Memory Study (WHIMS), one of the largest prospective randomized trials conducted 
to date, found that older women (mean age 69 years at enrollment) treated daily with a 
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combination of conjugated equine estrogens and medroxyprogesterone acetate were at 
significantly greater risk for stroke and dementia than placebo-treated controls (Shumaker et al., 
2004). Likewise, attempts to use estrogen therapy to reduce AD-related cognitive impairment in 
women have been largely unsuccessful (Henderson et al., 2000; Mulnard et al., 2000; Mulnard et 
al., 2004; Wang et al., 2000). Taken together, these studies have led to the ‘Window of 
Opportunity’ or ‘Critical Period’ hypothesis, which posits that estrogen therapy must be initiated 
at or near the time of menopause in order to positively affect brain aging and cognition. This is 
supported by recent animal studies which show that the beneficial effects of estrogens on 
cognitive performance in rats and mice diminish with age and time following loss of ovarian 
function when treatment is delayed (Daniel et al., 2006; Gibbs et al., 2009; Markowska and 
Savonenko, 2002; Talboom et al., 2008). 
 
IB. The Cholinergic Hypothesis 
The reasons for the loss of estrogen effect with age and time following menopause have 
yet to be explained. Cholinergic inputs to the hippocampus and cortex are known to play an 
important role in mediating effects of estrogens on cognitive performance (reviewed in (Gibbs, 
2010)).  Therefore, it is possible that deficits in cholinergic function that occur with age and time 
following menopause are responsible, at least in part, for the loss of estrogen effects.  
Cholinergic neurons in the medial septum (MS), diagonal band of Broca (DBB), and 
nucleus basalis magnocellularis (NBM) are the primary source of cholinergic inputs to the 
hippocampus and cerebral cortex (Figure 1) (Gritti et al., 1997; Mesulam, 1996; Woolf, 1991). 
These cholinergic projections are important for learning, memory, and attention (Baxter and 
Chiba, 1999; Everitt and Robbins, 1997). Early human studies demonstrate that anticholinergic 
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drugs produce cognitive impairments in young healthy adults similar to impairments seen in 
patients with dementia (Deutsch, 1971; Drachman and Leavitt, 1974), while cholinergic 
enhancing drugs improve performance in older patients (Drachman, 1977). Cholinergic lesions 
in the MS or NBM as well as use of selective muscarinic antagonists impair learning and 
memory (Everitt and Robbins, 1997). Moreover, cholinergic neurons in the basal forebrain 
(BFCNs) undergo degenerative changes during aging that correlate with progressive memory 
deficits (Bartus et al., 1982; Baxter and Chiba, 1999). Loss of BFCNs is a hallmark of 
Alzheimer’s disease and has been shown to play a role in the cognitive deficits associated with 
the dementia (Lanari et al., 2006; Linstow and Platt, 1999; Schliebs and Arendt, 2006; Smith et 
al., 1999). 
 
Figure 2. Illustration of the cholinergic pathways in the rat brain. Regions containing cholinergic 
neurons include the medial septum (ms), vertical and horizontal limbs of the diagonal band of 
 5 
Broca (vdb and hdb), nucleus basalis (bas), substantia innominata (si), laterodorsal tegmental 
nuclei (ldt), and peduncolopontine tegmental nuclei (ppt) (Image from Woolf, 1991).  
The ability of E2 to influence the functionality of the cholinergic system may contribute 
to the timing of the Window of Opportunity hypothesis. Following ovariectomy, E2 treatment 
can significantly enhance basal forebrain cholinergic function in females.  E2 treatment increases 
choline acetyltransferase (ChAT) activity (Luine, 1985), ChAT mRNA and protein (Gibbs, 1997; 
Gibbs, 2000; Singh et al., 1994), high-affinity choline uptake (O'Malley et al., 1987; Tinkler et 
al., 2004), and potassium-stimulated acetylcholine release in the hippocampus (Gabor et al., 
2003; Gibbs et al., 1997). E2 treatment also can increase the density of cholinergic fibers 
innervating specific regions of frontal cortex (Gibbs et al., 1997; Tinkler et al., 2004). These 
effects are relevant to effects on cognitive performance. For example, E2 treatment can attenuate 
the amnestic effects of scopolamine, a muscarinic acetylcholine receptor blocker in rats (Fader et 
al., 1998; Fader et al., 1999; Gibbs, 1999). A similar effect has been reported in humans (Dumas 
et al., 2006; Dumas et al., 2008). The effects of E2 on NMDA receptor binding and dendritic 
spine density in region CA1 of the hippocampus also appear to be mediated via cholinergic 
inputs (Daniel and Dohanich, 2001; Lam and Leranth, 2003). In addition, selectively destroying 
cholinergic projections to the hippocampus (Gibbs, 2002; Gibbs, 2007) or blocking M2 
muscarinic receptors in the hippocampus (Daniel et al., 2005) prevents E2 effects on spatial 
learning. This demonstrates that the cholinergic inputs are essential for mediating beneficial 
effects of E2 on certain tasks.  Notably, recent studies suggest that the effects of E2 on ChAT 
expression and cholinergic function are altered by age and time following ovariectomy (Bohacek 
et al., 2008; Gibbs, 1998; Gibbs, 2003; Gibbs et al., 2009; McMillan et al., 1996), which may 
account for the loss of beneficial effects of estrogen therapy on cognition in older women and in 
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women with AD. We propose that a better understanding of the mechanisms that underlie the 
effects of estrogens on BFCNs will lead to the development of more effective therapies for 
preventing and treating cognitive decline associated with aging and with AD. 
 
IC. Mechanisms of Estrogen Effects on Cholinergic Function 
The mechanism(s) by which E2 increases the functionality of BFCNs is unclear. Two 
nuclear estrogen receptors (ERs) have been identified, ER  and ER  (Toran-Allerand, 2004). 
These nuclear receptors regulate gene transcription but are also capable of activating second 
messenger signaling pathways such as mitogen-activated protein kinases (MAPK), 
calcium/calmodulin-dependent protein kinases (CamKII), and cAMP response element-binding 
proteins (CREB) (Manavathi and Kumar, 2006; McEwen, 2002). Approximately 30% of 
cholinergic neurons in the MS express ER , while less than 5% express ER  (Shughrue et al., 
2000). E2 can stimulate CREB activation in BFCNs in adult mice, and this effect was blocked by 
inhibition of MEK1/2 and by treatment with ICI182780 (an ER  and  antagonist) (Szego et al., 
2006). These effects were observed in ER  knockout mice but not in ER  knockout mice, 
suggesting that E2 may act through ER  to activate MAPK signaling and CREB 
phosphorylation in a subset of the cholinergic neurons. The different pathways of E2 signaling 
are shown in Figure 2. 
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Figure 3. Illustration of E2-signaling pathways (image by SABiosciences). Note that E2 
can bind to membrane-bound receptors (left and middle pathways) to activate signaling cascades, 
 8 
or directly enter the nucleus (far right) and bind to classical receptors to activate transcription 
factors. 
Recently, the novel membrane-associated estrogen receptor GPR30 was identified 
(Moriarty et al., 2006; Prossnitz et al., 2007). GPR30 is a seven-transmembrane-spanning G-
protein coupled receptor that is localized to both intracellular and plasma membranes (Funakoshi 
et al., 2006) and promotes rapid estrogen signaling in a variety of cell types including breast 
cancer cells, uterine epithelial cells, keratinocytes, thymus, and select cell lines (Albanito et al., 
2007; Filardo and Thomas, 2005; Thomas et al., 2005; Vivacqua et al., 2006). Radioligand 
assays have found that GPR30 shows specific, high affinity binding to E2 and related estrogens.  
In SKBR3 cells, GPR30 confers high affinity (Kd: 2.7 nM), saturable, low capacity (Bmax: 114 
pM) estrogen binding (Thomas et al., 2005). In Cos-7 cells, transfection with GPR30 confers E2 
binding with a Ki of 6.6 nM, and a Kd similar to that calculated for E2 binding in SKBR3 cells 
(Revankar, 2005). Heterologous expression studies and RNAi or antisense knock-down 
experiments confirm that binding is associated specifically with GPR30, and does not require 
classical estrogen receptors.  Competitive binding assays show that steroid binding to GPR30 is 
specific for E2 and for certain phytoestrogens, whereas other steroid hormones (e.g., 17 -
estradiol, progesterone, cortisol, and testosterone) have little binding at concentrations up to 10 
µM.  In contrast, the antiestrogens ICI182,780 and tamoxifen compete effectively, with relative 
binding affinities approximately 10% that of E2 (Thomas et al., 2005).  Functional studies using 
breast cancer cells lacking classical estrogen receptors found that GPR30 mediates up-regulation 
of the c-fos proto-oncogene by E2, as well as by other estrogen-like compounds such as the 
phytoestrogens genistein and quercetin (Maggiolini et al., 2004). Using Ishikawa cells (which 
express ER ) and human endometrial cancer cells (HEC1A cells; which do not express 
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functional ER ), Vivacqua et al. (Vivacqua et al., 2006) demonstrated that E2 and the major 
antiestrogenic metabolite of tamoxifen (4-hydroxytamoxifen) up-regulate c-fos expression 
specifically through interaction with GPR30, and that this effect involves activation of epidermal 
growth factor receptors.  
Both Northern blot and Western blot studies have confirmed that GPR30 is expressed in a 
variety of tissues, including the central nervous system. In the brain, GPR30 immunoreactivity 
has been detected in many regions including the hippocampus, hypothalamus, and midbrain 
(Brailoiu et al., 2007; Hammond et al., 2010). GPR30 also is expressed in spinal cord and in 
dorsal root ganglion neurons, and G-1, a selective GPR30 agonist (Bologa et al., 2006), can 
depolarize spinal cord neurons as well as stimulate protein kinase C -dependent hyperalgesia in 
rats (Dun et al., 2009; Kuhn et al., 2008). The role that GPR30 plays in mediating estrogen 
effects in brain is still largely unclear. A GPR30-selective agonist referred to as G-1 and the 
selective antagonist G-15 have been developed to better understand the role of GPR30 (Figure 3 
shows the structures of G-1 and G-15). One recent study found that G-1 reduces 5-HT1A 
receptor signaling in the paraventricular nucleus of the hypothalamus, analogous to E2 (Xu et al., 
2009).  Other studies suggest that GPR30 is involved in estrogen-mediated regulation of GnRH 
neurons in non-human primates (Noel et al., 2009; Terasawa et al., 2009).  Another study reports 
that G-1 significantly reduced freezing behavior in a mouse model of depression (analogous to 
E2) and that this effect was blocked by G-15 (a selective GPR30 antagonist) (Dennis et al., 
2009).   
 10 
   
Figure 4. Structures of G-1 (GPR30-selective agonist) and G-15 (GPR30-selective 
antagonist).  
Despite the evidence shown above, there is still controversy over whether GPR30 directly 
mediates estrogen effects. Otto et al. examined binding of E2 to GPR30 in different cellular 
systems and found no evidence for specific, saturable binding (Otto et al., 2008). Pedram et al. 
used SKBR3 cells (ER  negative, GPR30 positive) and found no significant binding of E2 and 
found non stimulation or ERK, PI3K, or cAMP signaling (Pedram et al., 2006). Moreover, a 
third group showed that the GPR30-selective agonist G-1 did not alter E2-induced gene 
expression in MCF-7 cells nor stimulate the expression of E2-responsive genes (Madak-Erdogan 
et al., 2008). Thus, these experiments do not support the hypothesis that GPR30 is a membrane-
bound estrogen receptor. 
Recently, four GPR30-knockout mice lines were generated to better delineate the role of 
GPR30 (Isensee et al., 2009; Martensson et al., 2009; Otto et al., 2009b; Wang et al., 2008). 
However, the observed phenotypes from these lines were diverse with only partial overlap. The 
varying phenotypes included increased body weight and visceral adiposity, impaired glucose 
tolerance, elevated blood pressure, or no phenotype at all. Different targeting strategies, genetic 
backgrounds, and experimental conditions may explain the conflicting observations (reviewed in 
(Langer et al., 2010)). 
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ID. Overview of Thesis: 
We have investigated the role of GPR30 in mediating estrogen effects on cholinergic 
neurons in the basal forebrain in rats, and have generated evidence that GPR30 is an important 
regulator of BFCN function with corresponding effects on cognitive performance. The major 
themes are as follows: (1) GPR30 mRNA and protein expression were observed throughout the 
rat forebrain and in regions important for learning and memory; (2) GPR30 agonism enhanced 
basal forebrain cholinergic function in a similar manner as E2; (3) GPR30 agonism enhanced 
spatial learning to that of gonadally intact rats, whereas antagonism impaired performance in a 
dose-dependent fashion. These themes will be described in greater detail in the following 
chapters. 
 
II. GPR30 EXPRESSION IN THE FOREBRAIN 
 
A. GPR30 Protein Expression 
 i. Overview 
Since estrogens have beneficial effects on learning and memory, and we hypothesize that 
GPR30 may directly mediate these effects, we first sought to determine whether GPR30 protein 
is found in regions of the brain that are implicated in learning and memory. At the start of this 
project no one had explored GPR30 expression in the rat brain. Therefore, GPR30 protein 
expression was first characterized in the rat forebrain using immunohistochemical methods. 
ii. Methods 
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Eight 3-4 month old OVX rats were anesthetized with a mixture of ketamine and xylazine 
and perfused with 0.9% saline followed by 4% paraformaldehyde/0.05 M sodium acetate (pH 
6.5) and then with 4% paraformaldehyde/0.05 M Tris (pH 9.0). Brains were removed, post-fixed 
for 2 hours in 4% paraformaldehyde/50 mM Sorenson’s phosphate buffer, and then stored in 
20% sucrose/50 mM PBS. Adjacent series of 40 m coronal sections were cut through the 
forebrain. Series were first incubated with a rabbit anti-GPR30 antiserum directed against the 
human C-terminus of GPR30 (0.1 g/mL in 50 mM PBS containing 0.05% Triton X-100 and 5% 
normal horse serum). The GPR30 antibody was a gift from Edward Filardo (Brown University). 
Sections were placed in primary antibody solution for 3 days at 4 C. The sections were rinsed 
with 50 mM PBS and then incubated with biotinylated goat-anti-rabbit IgG (Vector Laboratories, 
1:200 dilution) for 1 hour at room temperature. Sections were rinsed again with PBS and 
incubated with an avidin-HRP complex (Vectastain Elite kit; Vector Laboratories) for 1 hour at 
room temperature. Sections were rinsed with PBS, placed in 50 mM Tris-HCl (pH 7.6) 
containing 3,3’-diaminobenzidine (DAB; 0.5 mg/mL), then reacted with 50 mM Tris containing 
DAB (0.5 mg/mL), H2O2 (0.01%) and NiCl2 (0.032%) for 10 min. Sections were then rinsed 
with PBS, mounted onto Superfrost Plus slides (Fisher Scientific, Inc.), dehydrated, and 
coverslipped.  Specificity was tested by blocking staining with purified C-terminal peptide 
(Novus Biologicals, Inc.) at a concentration of 10 g/mL. Additional negative control sections 
were incubated with the secondary antibody but no primary antibody. 
iii. Results 
GPR30 immunoreactivity was detected in many rat forebrain regions, including the 
hippocampus, medial septum, frontal cortex, striatum, and nucleus basalis (Figure 1). Strong 
staining was seen in the cytoplasm and in some processes. Some cells were more strongly 
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labeled than others.  Staining was particularly strong in presumptive cholinergic cell groups 
(Figure 1B and 1C). Staining was greatly reduced in sections incubated with the GPR30 antibody 
plus 10 g/mL C-terminal blocking peptide (Figure 1F). Staining was not observed in sections 
that received no primary antibody.  
iv. Discussion 
The data show that GPR30 is expressed in many regions of the forebrain that are 
important for learning and memory including the hippocampus, frontal cortex, and striatum. 
These findings are consistent with and augment previous studies showing significant GPR30 
expression in hippocampus, and in specific regions of the hypothalamus and spinal cord 
(Brailoiu et al., 2007; Dun et al., 2009). In the hippocampus, E2 has many effects on 
connectivity, synaptic plasticity, and function (Spencer et al., 2008; Woolley, 2007). Among 
these effects are a significant increase in the number of dendritic spines and NMDA receptors on 
the apical dendrites of CA1 pyramidal cells, which are thought to contribute to estrogen effects 
on memory (Sandstrom and Williams, 2001; Sandstrom and Williams, 2004). Notably, these 
effects also are dependent on cholinergic afferents (Daniel and Dohanich, 2001; Lam and 
Leranth, 2003). In the frontal cortex, OVX decreases and E2 increases dendritic spine density in 
specific regions of the cortex in rats and nonhuman primates (Hajszan et al., 2007; Hao et al., 
2006; Tang et al., 2004), which likewise has been associated with effects on memory (Li et al., 
2004; Wallace et al., 2006; Wallace et al., 2007). The extent to which GPR30 plays a role in 
mediating these effects is currently unknown and needs to be investigated. 
Currently there are conflicting results regarding the cellular localization (cell surface 
versus endoplasmic reticulum) of GPR30 (Prossnitz et al., 2007). Previous studies using confocal 
fluorescence microscopy reported localization of GPR30 to the endoplasmic reticulum and Golgi 
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(Filardo et al., 2006; Revankar, 2005). Others have reported GPR30 localizes to the cell surface 
(Funakoshi et al., 2006; Thomas et al., 2005), as it co-localizes with concanavalin A, a plasma 
membrane marker (Filardo et al., 2007). In this study, GPR30 appeared to be located both on the 
cell surface and in the cytoplasm, which is consistent with the localization on the plasma 
membrane and endoplasmic reticulum (Figure 1). It should be emphasized, however, that this 
analysis was not designed to isolate expression within any given cellular compartment. There 
may be differences in the intracellular distribution of GPR30 based on cell type. For example, 
GPR30-IR in endothelial cells lining the third ventricle appear to localize differently within the 
cells compared with GPR30-IR in neurons (not shown). Further work is needed to better identify 
the subcellular localization of GPR30-IR within specific cells in the brain. 
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Figure 5. Photomicrographs illustrating GPR30-like immunoreactivity in different forebrain 
regions. (A) Frontal cortex, (B) medial septum, (C) striatum, (D) hippocampus, (E) CA3 region 
of hippocampus, and (F) CA3 region that was incubated with GPR30 antibody plus C-terminal 
peptide (Hammond et al., 2010). Scale bar = 50 m in panels A-C, E, and F. Scale bar = 200 m 
in panel D. Arrows point to several intensely labeled cells in regions containing cholinergic 
neurons.  
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B. GPR30 Co-localization with Selected Neuronal Types 
 i. Overview 
 Cholinergic neurons in the medial septum, diagonal band of Broca, and nucleus basalis of 
the rat forebrain are part of the basal forebrain cholinergic system and play roles in learning, 
memory, and attention (Baxter and Chiba, 1999; Everitt and Robbins, 1997). We hypothesized 
that GPR30 may be expressed by these neurons, thereby directly mediating estrogen effects on 
the cholinergic system and learning. Immunohistochemistry was used to evaluate GPR30 
expression in cholinergic and GABAergic neurons. 
 ii. Methods 
For co-localization studies, tissues were prepared from five 3-4 month old OVX rats and 
sections were incubated with the GPR30 antibody as described above. Sections were next 
incubated with a Cy3-labeled anti-rabbit IgG raised in donkey at a dilution (diluted 1:400; 
Jackson ImmunoResearch). Sections were then rinsed with PBS and incubated either with an 
antibody against ChAT (goat anti-ChAT, 1:1200 dilution; Chemicon International, Inc.) or with 
an antibody against parvalbumin (mouse anti-Parv, 1:16,000 dilution; Sigma-Aldrich, Inc.).  
Parvalbumin is one type of calcium- binding protein that is expressed by GABAergic neurons in 
the basal forebrain (Freund, 1989; Kiss et al., 1990).  These antibodies were detected using 
Alexa488-labeled secondary antibodies raised in donkey (diluted 1:400; Invitrogen). Negative 
controls underwent all processing steps, but omitted one or both primary antibodies. This 
controlled for non-specific staining and ruled out cross-reactivity between secondary antibodies.  
The order in which primary antibodies were added also was varied to control for order effects.  
Labeled cells were imaged using an Olympus Fluoview 1000 confocal microscope.  
Regions containing populations of cholinergic neurons were analyzed. These included the medial 
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septum, vertical (VDB) and horizontal (HDB) limbs of the diagonal band of Broca, nucleus 
basalis magnocellularis (NBM), and striatum (STR). Areas were defined by plate numbers in 
Paxinos and Watson (Paxinos et al., 1980). Sections through each region were selected from 
each rat and matched according to plate number (Table I). Within each section, the total number 
of ChAT- or Parv-immunoreactive cells in the region of interest and the percentage of these cells 
containing GPR30-IR were counted and calculated. Specific brain regions in which cells were 
counted are illustrated in Figure 1.  Cells were included in the counting if they contained ChAT- 
or Parv-IR, had a defined cell body and a detectable nucleus. Defined ChAT or Parv-
immunoreactive cells were first located and then examined for GPR30 labeling. Data are 
presented as average percentage of ChAT- and Parv-IR cells containing GPR30-IR per section. 
iii. Results 
Double-staining for GPR30 with ChAT and Parv is shown in Figure 2. No staining was 
seen in control sections incubated with secondary but not primary antibodies. Many ChAT-
GPR30 double-labeled cells were detected in regions containing basal forebrain cholinergic 
nuclei.  In comparison, few Parv-GPR30 double-labeled cells were detected. In the MS and STR, 
nearly all of the ChAT-IR cells detected also contained GPR30-IR (97% and 99%, respectively).  
In the VDB, HDB, and STR, 63%, 64%, and 80%, of ChAT-IR cells also contained GPR30-IR. 
In contrast, only 17%, 35%, 27%, and 0.4% of Parv-IR cells in the MS, VDB, HDB, and STR 
contained GPR30-IR. These data suggest that GPR30 is preferentially expressed by cholinergic 
neurons and that estrogens may bind to GPR30 to directly affect these neurons. 
iv. Discussion 
While the focus of this work was on cholinergic neurons, it should be noted that most of 
the cells containing GPR30-IR in the forebrain were not cholinergic. Many of these cells have 
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not been phenotypically identified; however, we did find that a subset of the parvalbumin-IR 
neurons in specific regions of the forebrain also contain GPR30-IR. In the medial septum, these 
neurons are GABAergic and synapse onto the dendrites of cholinergic neurons in the 
septum/diagonal band as well as project to the hippocampal formation (Leranth and Frotscher, 
1989). In addition, these neurons are excited by muscarinic agonists (Wu et al., 2000), and it has 
been shown that cholinergic neurons in the medial septum provide an excitatory drive to the 
GABAergic projections (Alreja et al., 2000). Like the cholinergic neurons, these GABAergic 
projections have been shown to play a role in specific cognitive processes (Zarrindast et al., 
2002). Hence, it is possible that activation of GPR30 on GABAergic neurons in the medial 
septum may contribute to the effects of E2 on cognitive performance. 
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Figure 6. Confocal images illustrating co-localization of GPR30-IR with ChAT (A, D, G, J), as 
well as examples of Parv-labeled cells lacking GPR30-IR (B and C) (Hammond et al., 2010). 
Panels A and B show sections through the striatum, C-F show sections through the medial 
septum, G-I show sections through the nucleus basalis, and J-L show sections through the 
vertical limb of the diagonal band of Broca. The insets in panels A and B show indicated neurons 
at double the magnification. Panels E and F are unmerged images of D. H and I are unmerged 
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images of G. K and L are unmerged images of J. ChAT- or Parv- staining is green. GPR30-IR 
staining is red. Double-labeled cells appear orange/yellow. Scale bar = 50 m in A-F and J-L and 
80 m in G-I. 
 
C. Expression and Co-localization in the Monkey Forebrain 
 i. Overview 
 We hypothesize that GPR30 protein and co-localization with cholinergic neurons is not 
limited to the rat brain and can be seen in other species. Immunohistochemistry was used to 
evaluate GPR30 expression in the rhesus monkey forebrain. 
ii. Methods  
Perfused rhesus brain tissues were a gift from Dr. Tony Plant (University of Pittsburgh). 
Blocks of tissue containing the septum from untreated 4 one year old gonadally intact adult male 
rhesus monkeys (Macaca mulatta) were sectioned at 30 m and processed for GPR30 and ChAT 
immunoreactivity as is described in the preceding section. 
iii. Results/Discussion 
Double-staining for GPR30 with ChAT is shown in Figure 3. No staining was seen in 
control sections incubated with secondary but not primary antibodies. Many ChAT-GPR30 
double-labeled cells were detected in regions containing basal forebrain cholinergic neurons. 
These data are consistent with the hypothesis that GPR30 is preferentially expressed by 
cholinergic neurons and that estrogens may bind GPR30 to directly affect these neurons. 
Moreover, they show that GPR30 is expressed in the forebrains of other animal models. 
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Figure 7. Confocal images illustrating co-localization of GPR30-IR with ChAT in the medial 
septum (A) and vertical limb of the diagonal band of Broca (B) in the rhesus brain. ChAT 
staining is green and GPR30 staining is red. Double-labeled cells appear orange/yellow. Scale 
bar = 50 m  
 
D. GPR30 mRNA Expression 
 i. Overview 
One limitation of immunohistochemical studies is that antibodies can bind to proteins 
other than the target protein that have similar structures. To address this limitation a RT-PCR 
assay was developed to verify the presence of GPR30 mRNA as well as compare relative levels 
of GPR30 mRNA in different regions of interest, such as the hippocampus, cortex, medial 
septum, and striatum. We hypothesized that GPR30 mRNA is present in the regions in which we 
saw GPR30-like immunoreactivity, and that mRNA levels would also be highest in regions with 
the largest numbers of immunoreactive neurons. 
 ii. Methods 
Three adult OVX rats were anesthetized, decapitated, and brains were removed and 
dissected. Using a brain matrix, the anterior portion of the brain (+4.70 mm from Bregma) was 
discarded. The next 3 mm (4.70 - 1.70 mm from Bregma) containing frontal and prefrontal 
A B 
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cortex were collected. Prefrontal cortex included regions Cg1, Cg2, and Fr2. Frontal cortex 
included regions Fr1 and Fr3. Next, a 3 mm slab (1.70 to -1.30 mm from Bregma) was collected 
containing the septum/VDB and striatum. The septum/VDB was dissected by collecting tissue 
between the lateral ventricles and anterior commissure.  The hippocamapus was dissected from 
the remaining tissues. An example of a rat brain in the brain matrix is shown in Figure 4. 
 
Figure 8. Rat brain in a matrix. Horizontal lines delineate where the brain is cut. Spacing 
between lines is 1 mm. Image from (Liu and Smith, 2003).  
All tissues were frozen at -80 C. TRIzol (Invitrogen, Inc.) was added to each sample and 
total RNA was isolated as per manufacturer’s instructions. mRNA was then reverse transcribed 
using the SuperScript III kit (Invitrogen, Inc.).  Real-time PCR was performed using SYBR 
green and an ABI 7300 Sequence Detection System (ABI). All samples were run in duplicate, 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to control for amount of 
mRNA added to the reaction. Negative controls for RT and PCR reactions included no template 
and no enzyme and also were performed in duplicate. The following primer sequences were used 
(listed in 5’-3’ direction):  
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GPR30 sense: AGGAGGCCTGCTTCTGCTTT  
GPR30 antisense: ATAGCACAGGCCGATGATGG  
GAPDH sense: TGCCACTCAGAAGACTGTGG  
GAPDH antisense: GGATGCAGGGATGATGTTCT 
These primers were created using Invitrogen’s Oligoperfect Designer. The coding sequence 
near the C-terminus was amplified, and these primers were generated to be 18-20 bases long, to 
have a primer Tm of 60-63 C, a GC content of 50%-55%, and to generate a product size of 80-
130 base pairs. Data were analyzed using Sequence Detection System (SDS) software (ABI, 
Inc.), and results were obtained as Ct (threshold cycle) values. The average Ct for each set of 
duplicates was calculated. Relative expression of GPR30 was normalized to GAPDH by 
subtracting the average Ct for GAPDH from the average Ct for GPR30 (∆Ct) for each region per 
rat. The average ∆Ct for each region was then calculated. Levels of GPR30 mRNA relative to the 
hippocampus were than calculated by subtracting the average ∆Ct for each region from the 
average ∆Ct for the hippocampus (∆∆Ct). Approximate GPR30 mRNA levels for each region 
were then calculated using the 2-∆∆Ct method (Pfaffl, 2001). This entire process was performed 
three times, and ANOVA was used to determine significant differences in expression across 
brain regions.  
 Studies were first done to validate this assay and specifically to verify that the designed 
primers worked and that increasing amounts of starting material resulted in a logarithmic 
increase in detection of mRNA levels. cDNA was created from the hippocampus of four vehicle 
treated rats. Results of this validation are shown in the Figure 5. 
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Figure 9. Graph showing that increasing amounts of starting material (cDNA) resulted in 
decreasing cycle number to detection threshold. n=4 per primer.  
 iii. Results/Discussion 
Results confirmed that GPR30 mRNA could be detected in each region analyzed. 
Relative levels differed depending on the region of interest. The highest levels were detected in 
the hippocampus, whereas lowest levels were detected in the septum and striatum (Figure 4). 
Post-hoc analysis confirmed that levels of GPR30 mRNA in the septum were significantly lower 
than in the hippocampus (p<0.05). This data confirms immunohistochemical data showing 
GPR30 immunoreactivity in the regions analyzed and supports the hypothesis that GPR30 may 
play a role in mediating estrogen effects in these regions. 
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Figure 10. Bar graph comparing relative GPR30 mRNA levels in different brain regions 
(Hammond et al., 2010). Bars represent mean levels of GPR30 mRNA  SEM relative to mean 
levels in the hippocampus. HPC: hippocampus; PFX: prefrontal cortex; FCX: frontal cortex; MS: 
medial septum; STR: striatum. N = 3, *p < 0.05 relative to mean levels in the hippocampus. 
III. GPR30 AND BASAL FOREBRAIN CHOLINERGIC FUNCTION 
A. Acetylcholine Release 
 i. Overview  
Since we hypothesize that GPR30 mediates the ability of E2 to enhance the basal 
forebrain cholinergic system, in vivo microdialysis and HPLC were used to compare the effects 
of G-1 with E2 on potassium-stimulated ACh release in the hippocampus, one measure of basal 
forebrain cholinergic function. 
 ii. Methods 
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Twelve OVX rats were administered E2, G-1, or vehicle using an Alzet osmotic 
minipump (model 2002; Durect Corp., Inc.) implanted subcutaneously in the dorsal neck region. 
Rats were anesthetized with a combination of ketamine (50 mg/ml) and xylazine (10 mg/ml) 
(0.25 cc/250 g.b.w. i.p.) For the pumps a small in incision in the skin overlying the dorsal neck 
region was made, the capsule was implanted, and the incision was closed with a 9 mm wound 
clip. Drugs were administered continuously at a dose of 5 µg/day for one week. This dose was 
selected based on our previous study which showed that 5 µg/day of either G-1 or E2 enhanced 
acquisition of a DMP T-maze task (Hammond et al., 2009). E2 was diluted in a vehicle of 13.9% 
DMSO + 20% hydroxypropyl-ß-cyclodextrin (HPβCD).  G-1 was administered in a vehicle 25% 
DMSO+ 13.3% HPβCD. Half of the control group was treated with each of the vehicle solutions. 
At the time of pump implantation rats also received a microdialysis guide cannula (CMA 12 
Elite Guides, CMA Microdialysis, Inc.) lowered into the right hippocampus (-3.4 mm bregma, 
1.18 mm lateral, -3.4 mm ventral) and fixed to the skull using stainless steel screws and 
craneoplastic cement (Plastics One, Inc.). Dummy cannulae were inserted into the guide 
cannulae to retain patency. Microdialysis was performed 7 days later. Following implantation 
and cannulation rats were placed on a warm heating pad during recovery. Ketofen (1 mg/kg s.c.) 
was administered twice per day for three days to reduce discomfort. 
Concentric, 3 mm microdialysis probes were used (CMA 12 Elite Probes, CMA 
Microdialysis, Inc.).  Probes were perfused at a rate of 1 l/min with artificial cerebrospinal fluid 
(ACSF; 144.3 mM NaCl, 4.0 mM KCl, 1.2 mM CaCl2, 1.0 mM MgCl2, 1.7 mM Na2HPO4, 0.5 
mM NaH2PO4) containing 0.8 M neostigmine bromide. On each day of microdialysis, probes 
were first dialyzed for 30 minutes against a solution of ACSF containing 0.1 pmol ACh/20 µL.  
This sample was used to calculate and correct for probe efficiency (efficiencies averaged around 
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30%).  The probe was then inserted through the cannula into the hippocampus. The rat was 
placed into a large plastic container for the duration of the experiment. Dialysates were collected 
continuously. Samples were collected and frozen every 30 min.  After waiting 90 minutes for 
basal ACh release to stabilize, two additional samples were collected over one hour and were 
averaged to represent basal ACh release.  Next probes were perfused with identical ACSF 
containing 60 mM potassium and samples were collected after 30 and 60 min. Probes were then 
perfused again with the ACSF containing 4.0 mM potassium and samples were collected every 
30 minutes for an additional 60 minutes. 
Dialysates were analyzed using HPLC, enzymatic conversion, and electrochemical 
detection as previously described (Rhodes et al., 1996). An ESA HPLC system was used.  Flow 
rate was 0.35 µL/min.  Mobile phase consisted of 100 mM di-sodium hydrogen phosphate 
anhydrous (Fluka, Inc.), 1-Octanesulfonic acid (Sigma-Aldrich, Inc.), Reagent MB (ESA, Inc), 
and the pH was adjusted to 8.0 using phosphoric acid.  Samples were passed through a Shiseido 
Capcell Pak C18 MGII column, 100A, 3micron, 1.5 x 75mm, and then through a solid-phase 
reactor (ESA, Inc.) containing acetylcholinesterase and choline oxidase at 35 ˚C.  The resulting 
H2O2 was detected with a model M5040 electrochemical cell attached to a Coulochem model 
5300 detector (ESA, Inc.).  Chromatograms were analyzed using EasyChrome software.  ACh 
standards were prepared in ACSF.  Twenty microliters of each sample was injected. All 
standards were run in duplicate.  Quantity of ACh was determined by measuring area under the 
ACh peak. This assay was able to detect as little as 30 fmol of ACh per 20 µL sample. Values 
from in vivo dialysates were then corrected for probe recovery and expressed as picomoles per 
20 l sample. The two samples collected prior to the switch to high potassium were averaged as 
an estimate of basal ACh release.  Subsequent samples were used to calculate percent change in 
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ACh release relative to baseline for each rat.  In this way, each rat served as its own control for 
estimating potassium-stimulated release.  Percent change that was calculated from the two 
samples collected over 60 minutes after switching to high potassium were averaged as a measure 
of percent change from basal release during the 60 minute period.  Remaining samples were 
evaluated to verify that release declined after switching back to low potassium.  This was done 
for each rat.  Average basal and potassium-stimulated release was then calculated for each 
treatment group.  Effects of treatment on basal and potassium-stimulated release were analyzed 
using one-way ANOVA followed by a Tukey test. 
 iii. Results 
Treatment with either G-1 or E2 had no significant effect on basal extracellular levels of 
ACh in the hippocampus.  Basal levels were 0.38 0.02, 0.34 0.03, and 0.46 0.03 pmol/20µL for 
controls, G-1 and E2-treated rats respectively.  In contrast, treatment with G-1 or E2 produced 
substantial increases in potassium-stimulated ACh release (Figure 5). The average percent 
change relative to baseline was 135.4 6.8% for controls, versus 290.7 21.2% and 289.8 28.9% 
for G-1 and E2-treated groups. ANOVA revealed a significant effect of Treatment (F[2,9]=4.50, 
p < 0.04). Post-hoc analysis revealed that E2 and G-1 treatments differed significantly from 
OVX controls but not from each other. Following return to low potassium, levels of extracellular 
acetylcholine declined (not shown).  
iv. Discussion 
G-1 was able to enhance potassium-stimulated ACh release to a similar extent as E2. This 
suggests that activation of GPR30 alone may be sufficient to mediate this effect. Cell culture 
studies show that G-1 does not bind to ER  or ER , produces effects in cells expressing GPR30 
but lacking ER  or ER , and does not produce effects in cells lacking GPR30 (Bologa et al., 
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2006). This suggests that the effects of G-1 on ACh release are not due to G-1-mediated 
activation of ER  or ER . In the SKBR3 cell line, which expresses GPR30 but not ER  or ER , 
knockdown of GPR30 decreases E2 binding by 80% and blocks E2 signaling (Thomas et al., 
2005), suggesting that GPR30 alone can mediate E2 effects. These results are somewhat 
controversial. Results showing a lack of GPR30 involvement in E2 signaling in mouse 
endothelial cells as well as SKBR3 cells also have been reported (Pedram et al., 2006), although 
there is evidence for a direct role of GPR30 signaling in keratinocytes (Kanda and Watanabe, 
2004). It remains to be determined whether GPR30 alone is sufficient to account for effects of 
E2 on ACh release. 
 Even if GPR30 plays a significant role (as suspected) in mediating effects of E2 on ACh 
release, this does not mean that all effects of E2 on BFCNs are mediated by GPR30. Szego et al. 
showed that E2 administered either in vivo or in vitro induces pCREB in approximately 30% of 
the cholinergic neurons in the medial septum and substantia innominata of OVX mice, that this 
involved activation of the MAP kinase pathway, and that this occurred in ER  knock-out, but not 
ER  knock-out mice (Szego et al., 2006). These data suggest that E2 can directly affect a 
subpopulation of cholinergic neurons in medial septum and substantia innominata via ER . 
Whether E2 activation of MAPK and CREB involve activation of GPR30 is not yet known. The 
fact that effects were not observed in ER  knock-out mice, however, suggests that activation of 
GPR30 alone cannot be sufficient. One possibility is that activation of GPR30 does not play a 
role in mediating these effects. Another possibility is that signaling via ER  cooperates with 
signaling via GPR30 to mediate effects on cholinergic function, perhaps via different signaling 
pathways. For example, the MCF-7 cell line expresses both GPR30 and ER , and some studies 
show that E2 signaling via either receptor can induce c-fos expression in these cells (Maggiolini 
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et al., 2004). Further, it has been shown that E2-bound ER  and ER  can regulate the expression 
of target genes either directly or indirectly via protein-protein interactions with other 
transcription factors (reviewed in (Truss and Beato, 1993). Further studies are needed to identify 
the extent to which GPR30 is responsible for mediating the effects of E2 on basal forebrain 
cholinergic function.  
 
Figure 11. Bar graph showing percent change in ACh release in response to elevated 
potassium (Hammond et al., 2010). Bars represent average percentage change from baseline  
SEM. *p < 0.05 relative to vehicle-treated animals. n = 4 per group.  
 
B. Induction of pCREB and pERK in cholinergic neurons 
i. Overview 
To further test the hypothesis that GPR30 mediates the ability of E2 to enhance the basal 
forebrain cholinergic system, we next sought to examine E2 effects on cholinergic neurons at the 
cellular level. Immunohistochemical methods were used to evaluate the rapid induction of 
pCREB and pERK within ChAT-positive neurons in response to intracerebroventricular (ICV) 
infusions of E2 or vehicle.  
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ii. Methods 
8 adult Ovx Sprague-Dawley rats were used. Rats were anesthetized with a mixture of 
ketamine (50 mg/ml) and xylazine (10 mg/ml) and placed into a standard stereotaxic apparatus. 
The skull was exposed and a hole drilled 1.2 mm lateral from midline and +0.2 mm from 
Bregma. A cannula was lowered 3.3 mm into the lateral cerebral ventricle. Rats received 1 l 
infusions of 1, 3, or 10 M E2 or vehicle for a total of five minutes to allow for diffusion. Rats 
were then euthanized after five minutes and the brains processed as described above. Sections 
were pretreated with 1 % NaBH4 in 50 mM PBS for 30 minutes followed by treatment with 0.3% 
H2O2 in 50 mM PBS for 10 minutes. They were then incubated with an antibody against pCREB 
(1:500 dilution) or pERK (1:5000) for three days at 4 C. Sections were then incubated for one 
hour at room temperature with a biotinylated donkey anti-rabbit secondary antibody (1:200 
dilution) and then processed using avidin-biotin-HRP methods. Next, sections were incubated 
with a goat anti-ChAT primary antibody (1:1200 dilution) for three days at 4 C and then 
incubated with a biotinylated horse anti-goat secondary antibody (1:200) for one hour at room 
temperature. Sections were then processed using a Vector Red alkaline phosphatase kit. The 
reaction product was assessed using standard light microscopy. We quantified the number of 
ChAT labeled neurons that also stained positive for pCREB and pERK in the medial septum. We 
used approximately 5 sections per region per animal between plate numbers 14-18. Sections 
were selected based on plate number and similar plate numbers were compared across treatment 
groups.  
iii. Results/Discussion 
No differences were seen when the number of ChAT and pCREB double-labeled cells 
were compared across the different E2 treatments. In the plates analyzed pCREB staining could 
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be seen throughout the septum, but this staining was seen in less than 2% the nuclei of 
cholinergic neurons in all treatment groups (Figure 4). Also, no differences were seen between 
the different estradiol treatments and the number of ChAT+pERK double-labeled cells. The 
majority of pERK staining was seen in the lateral areas of the septum and in the cortex.  
 
 
Figure 12. Image showing one of the few examples of ChAT and pCREB co-localization in the 
medial septum. The neuron in the rectangle is shown at the bottom right at a higher 
magnification. ChAT neurons are labeled in red and pCREB neurons are labeled in brown-black. 
Scale bar equals 50 m. 
 
However, dose-dependent changes in pERK and pCREB expression in the cortex and 
hippocampus were seen, as evidenced by increased staining in the hippocampus (Figure 6), but 
these were not quantified.  
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Figure 13. Images comparing pCREB expression in the dentate gyrus and CA3 regions of the 
hippocampus in response to E2 infusions. Panel A shows minimal pERK expression in response 
to vehicle infusion. Panel B shows moderate expression of pERK following 1 M E2 treatment. 
Panels C and D show intense pCREB labeling following 3 M and 10 M E2, respectively. 
 
We planned to examine the ability of G-1 to induce activation of pERK or pCREB in 
cholinergic neurons similar to E2. Since we were unable to find any acute E2-induced changes in 
pCREB or pERK expression in cholinergic neurons, we did not examine G-1 effects. The fact 
that we saw concentration-dependent changes in pCREB expression in the hippocampus suggests 
that the methodology used was valid. Thus, no change in pCREB or pERK expression in 
cholinergic neurons across varying E2 doses could be due to the time of sacrificing. Future work 
A B 
C D 
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could examine the effects of varying doses at longer time points after the initial E2 infusion. 
Currently we are replicating the finding of E2-induced pCREB expression in the hippocampus 
and will determine whether G-1 induces a similar effect. 
 
C. Choline Acetyltransferase Activity 
 i. Overview 
 Choline Acetyltransferase (ChAT) is the enzyme that couples acetyl-CoA to choline, 
resulting in the formation of acetylcholine, and its activity is a commonly used measure of basal 
forebrain cholinergic function. E2 has been shown to increase ChAT activity in regions such as 
the frontal cortex and hippocampus (Kaufman et al., 1988; Luine, 1985), so a ChAT assay was 
used to compare the effects of G-1 with E2 on ChAT activity. This experiment further tests the 
hypothesis that GPR30 mediates estrogen effects on cholinergic function, and we predicted that 
G-1 would increase ChAT activity similar to E2. 
 ii. Methods 
 ChAT activity was measured in the prefrontal cortex, frontal cortex, medial 
septum/diagonal band, and hippocampus of 17 OVX rats treated with vehicle, E2 (5 g/day for 1 
week), or G-1 (5 g/day for 1 week). Frozen tissues were thawed and dissociated by sonication 
in a medium containing EDTA (10 mM) and Triton X-100 (0.5%) (10 mg tissue/ml). An aliquot 
of each sample was used for the determination of total protein. To measure ChAT activity, three 
5- l aliquots of each sample were incubated for 30 min at 37 C in a medium containing 
[3H]acetyl-CoA (50,000-60,000 d.p.m./tube, final concentration 0.25 mM acetyl CoA, Sigma, St. 
Louis, MO), choline chloride (10.0 mM), physostigmine sulfate (0.2 mM), NaCl (300 mM), 
sodium phosphate buffer (pH 7.4, 50 mM), and EDTA (10 mM). The reaction was terminated 
 35 
with 4 ml sodium phosphate buffer (10 mM) followed by the addition of 1.6 ml of acetonitrile 
containing 5 mg/ml tetraphenylboron. The amount of [3H]acetylcholine produced was 
determined by adding 8 ml of EconoFluor scintillation cocktail (Packard Instruments, Meriden, 
CT) and counting total c.p.m.s in the organic phase using an LKB beta-counter. Background was 
determined using identical tubes to which no sample was added. For each sample, the three 
reaction tubes containing sample were averaged and the difference between total c.p.m.s and 
background c.p.m.s was used to estimate the total amount of acetylcholine produced per sample. 
ChAT activity was then calculated for each sample as pmol acetylcholine produced/hr/ g 
protein, and these values were analyzed for each treatment group by one-way ANOVA. 
 iii. Results/Discussion  
 No significant effects were observed between either the E2 or G-1 group compared with 
vehicle controls, though there were trends for higher ChAT activity in the prefrontal cortex 
(p=0.1) in rats treated with E2 or G-1 versus controls. One explanation is that our sample size 
was not large enough to capture a significant difference, especially since there was considerable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
variability in some regions. Another explanation is that E2 and G-1 do not have a significant 
effect on ChAT activity at this specific dose and/or time point. Previous work from our lab 
shows that E2 does enhance cholinergic activity, but that this enhancement varies with the 
manner, regimen, and duration of hormone treatment (Gibbs, 2000). Specifically, it was found  
that short-term treatment (i.e. 2 weeks) with E2 enhanced cholinergic function within specific 
targets, whereas long-term repeated or continuous administration (greater than 4 weeks) 
produced no significant changes. 
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Figure 14. Bar graph comparing acetylcholine production in different regions following 
treatment with vehicle, E2, or G-1. Bars represent pmol acetylcholine produced/hr/ g protein  
SEM. PFX: prefrontal cortex; FCX: frontal cortex; MS: medial septum; STR: striatum; HPC: 
hippocampus; HPCD: hippocampus from side containing cannula. n=5-6 per group. 
 
D. GPR30 mRNA Expression and Cholinergic Lesions 
 i. Overview 
 Cholinergic lesions in the medial septum have been shown to impair the ability of 
estradiol to enhance spatial learning (Gibbs, 2002). We hypothesized that this may be due to 
downregulation of estrogen receptor expression in the hippocampus, a key brain region that 
receives basal forebrain cholinergic input and that is required for memory consolidation. RT-
PCR was used to examine the effects of cholinergic lesions on estrogen receptor mRNA 
expression in the hippocampus. 
 ii. Methods  
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Six young adult female rats were used. Rats received intraseptal injections of 192IgG-
saporin (SAP) or vehicle. 192IgG-SAP is a conjugate of a mouse monoclonal antibody to rat 
p75NTR and the ribosome-inactivating protein saporin. Since only cholinergic neurons express 
the p75NTR antigen, they are selectively destroyed by the immunotoxin. One week after 
treatment rats were sacrificed and the brains dissected. Tissues from the septal region were 
immersion-fixed and later sectioned. Immunohistochemical methods were used to examine 
ChAT labeling and verify successful lesions. The hippocampus was dissected and frozen at -
80 C. TRIzol (Invitrogen, Inc.) was added to each sample and total RNA was isolated as per 
manufacturer’s instructions. mRNA was then reverse transcribed using the SuperScript III kit 
(Invitrogen, Inc.). The following primer sequences were used (listed in 5’-3’ direction):  
GPR30 sense: AGGAGGCCTGCTTCTGCTTT  
GPR30 antisense: ATAGCACAGGCCGATGATGG  
ER  sense: TCCGGCACATGAGTAACAAA 
ER  antisense: TGAAGACGATGAGCATCCAG 
ER  sense: AAAGTAGCCGGAAGCTGACA 
ER  antisense: ACTGCTGCTGGGAGGAGATA 
GAPDH sense: TGCCACTCAGAAGACTGTGG  
GAPDH antisense: GGATGCAGGGATGATGTTCT 
  Real-time PCR was performed using SYBR green and an ABI 7300 Sequence Detection 
System (ABI). All samples were run in duplicate, a standard curve was generated, and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to control for amount of mRNA 
added to the reaction.  
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Figure 15. Bar graph showing relative ER expression in response to saline or saporin infusions. 
Bars represent delta Ct values of ER levels that are normalized to GAPDH control mRNA  
SEM. n=3 per group. 
 iii. Results/Discussion 
 No significant differences were found between SAP-treated and control rats for any of 
the ERs examined. Though SAP selectively destroyed the cholinergic neurons in the septum that 
project to the hippocampus (immunostaining was used to verify that cholinergic neurons in the 
MS were destroyed), the immunotoxin had no noticeable effect on ER expression in the 
hippocampus. This suggests that SAP does not impair E2 performance on spatial learning via 
disruption of estrogen receptors in the hippocampus. It is possible that disruption of the direct 
effects of E2 on cholinergic neurons in the medial septum is responsible for the impaired 
learning seen with cholinergic lesions.  
 
 
IV. GPR30 AND COGNITIVE PERFORMANCE 
A. T-Maze Acquisition 
1. Comparison of G-1 and selective estrogen receptor agonists 
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 i. Overview 
We hypothesize that GPR30 mediates estrogen effects on spatial learning, so we tested 
the ability of a GPR30 selective agonist to enhance learning and compared this with other 
estrogen receptor selective agonists. Rats were chronically administered G-1 (GPR30 selective 
agonist), PPT (ER  selective agonist), DPN (ER  selective agonist), or E2 and tested on a 
delayed matching-to-position (DMP) T-maze, a task that tests spatial learning and working 
memory. 
 ii. Methods 
Animals: 
A total of sixty-eight 3-4 month old female Sprague-Dawley rats (300-350 g) were 
purchased from Hilltop Laboratories. Rats were ovariectomized (with the exception of the 
gonadally intact group) prior to delivery and individually housed on a 12-hour day/night cycle 
with food and water available ad libitum. All procedures were carried out in accordance with 
PHS policies on the use of animals in research, and with the approval of the University of 
Pittsburgh’s Institutional Animal Care and Use Committee. 
Treatments: 
Two weeks prior to behavioral training, animals were handled daily, food restricted, and 
maintained at 85% of normal body weight during acquisition and testing. Rats were administered 
estradiol (Sigma Chemicals; St Louis, MO), G-1 (Calbiochem; La Jolla, CA), DPN (Tocris 
Cookson; Ellisville, MO), PPT (Tocris Cookson; Ellisville, MO), or vehicle by Alzet model 
2006 mini-osmotic pumps implanted s.c. in the dorsal neck region. Gonadally intact rats received 
sham surgeries. The pumps delivered a volume of 0.15 l per hour over 42 days. G-1 has been 
shown to be an agonist specific to GPR30 – competitive binding studies showed that G-1 did not 
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compete with estradiol binding in COS7 cells transfected with either ERα or ERβ, whereas as it 
did compete with binding in COS7 cells transfected with GPR30 (Bologa et al., 2006). The ERα 
agonist used was propylpyrazole triol (PPT), a triarylpyrazole found to be approximately 410-
fold more selective for ERα than ERβ (Kraichely et al., 2000; Stauffer et al., 2000). The ERβ 
agonist used was diarylpropiolnitrile (DPN), a compound with 70-fold higher relative binding 
affinity and 170-fold higher relative potency for ERβ over ERα (Meyers et al., 2001). 
E2, DPN, and PPT treatments were administered at a rate of 5 g/day at concentrations of 
1.39 mg/ml in vehicles consisting of 13.9% DMSO + 20% hydroxypropyl-β-cyclodextrin 
(HPβCD).  G-1 treatments were also administered at a rate of 5 g/day at a concentration of 1.39 
mg/ml in a vehicle 33.7% DMSO+ 13.3% HPβCD. Previous literature was used to select doses 
of E2, PPT, and DPN (Gibbs et al., 2004; Walf et al., 2004), but because no previous research 
has been published using G-1, the dose was chosen to be similar to the other agonists based on 
molecular weight. Vehicle controls contained either one of the vehicles listed above minus any 
drug treatment.  
Behavior: 
The DMP task is a spatial learning and memory T-maze task. The T-maze consists of an 
approach alley (4 in. wide x 14 in. long) and two goal arms (4 in. wide x 12 in. long). The walls 
of the maze are 5 in. high, and the doors are constructed of clear plexiglass, thus allowing 
animals to view the surrounding room. Sliding doors are positioned 8 in. down the approach 
alley and at the entrance to each goal arm.  
Behavior training was performed as previously described (Gibbs, 1999). Testers were 
blinded to what rat belonged in each treatment group. Animals were first adapted to the maze by 
placing them in the maze with food (formula 5TUM 45 mg pellets from Test Diets, Inc.) for 5 
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days. Starting on day 6 through 9 animals were trained to run to the ends of the goal arms by 
using a series of forced choices and rewarding with four pellets. Right and left arms were 
alternated to avoid introducing a side bias. Next, animals began DMP testing, which was 
performed as 8 trial pairs per day. The first trial of each pair consisted of a forced choice in 
which one arm was blocked, forcing the animal to enter the unblocked arm to receive the food 
reward. The animal was then returned to the approach alley for the second trial in which both 
goal arms were open. A choice was defined as the animal placing both front legs and part of both 
rear legs into a goal arm. Returning to the same arm as the forced choice trial resulted in a food 
reward, while entering the incorrect arm resulted in no food reward and confinement for 10 
seconds. Forced choices were randomized and balanced to avoid introducing a side bias. 
Animals were run in squads of 4 to 6. After each trial pair, the animal was returned to its home 
cage for 5-10 min while other animals were tested. Animals received 8 trial pairs per day until 
they reached the criterion of at least 15/16 correct choices over two days. 
After reaching criterion, animals received a probe trial during which the T-maze was 
rotated 180° (relative to extramaze cues) between the forced and open trial. This was done to 
assess whether rats were using a place strategy (relying on extramaze cues) or a response 
strategy (independent of extramaze cues) to perform the task. Rats using a place strategy would 
be impaired by maze rotation, whereas rats using a response strategy would be unaffected. For 
analysis purposes, rats were given a score of 1 if they entered the same goal arm during the open 
choice and a score of 0 if they entered the opposite arm. After the probe trial, animals received 8 
trial pairs per day for 4 days with increased intertrial delays (10, 30, 60, 90 seconds on each of 
the 4 consecutive days). 
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Following training, animals were given an overdose of ketamine (40 mg/kg) and xylazine 
(28 mg/kg) injected i.p. and euthanized by decapitation. Trunk blood was collected for the 
determination of serum E2 and luteinizing hormone (LH) levels. For estradiol analysis, samples 
were extracted with ether and resuspended in buffer. Samples were then analyzed in duplicate by 
RIA using a kit from Diagnostic Systems Laboratories, Inc. (Webster, TX). All samples were 
analyzed in one assay.  The estradiol assay was performed by the assay core of the Center for 
Reproductive Physiology at the University of Pittsburgh. The minimum detectable dose was 1.2 
pg/ml, and the intra-assay CV was 5.8%. Samples also were analyzed for circulating levels of 
LH.  Samples were assayed in singlet using a sensitive sandwich immunoradiometric assay by 
the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core. 
This assay had a reportable range of 0.07 – 37.4 ng/ml with a sensitivity of 0.07 ng/ml. The inter- 
and intra-assay CVs were 10% and 5%, respectively.    
Data Analysis  
Rate of acquisition was defined as the number of days to reach criterion (DTC). DTC was 
analyzed for each treatment group by one-way ANOVA. Learning curves were constructed by 
plotting the mean performance (percent correct) for each group across Blocks of training. Each 
Block represented average performance across three consecutive days of training. Upon reaching 
criterion, a value of 93.8% correct, reflecting the criterion of 15/16 correct choices over 2 days, 
was used in calculating group performance on subsequent days. The learning curves were 
compared using a two factor (Treatment x Block) ANOVA with repeated measures on Block. 
Performance on the probe trial was analyzed by contingency table and Chi-square. Performance 
during the increased intertrial delays was analyzed by ANOVA with repeated measures on 
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Delay. Post-hoc comparisons were made using a Tukey test. Significance was set at p ≤ 0.05. All 
statistical analysis was performed using JMP software for Macintosh.  
 iii. Results 
Serum estradiol levels: 
The mean levels of E2 in the E2 treatment group were 116.0  39.6 pg/ml, with a range 
of 65.0-166.1 pg/ml. Mean E2 levels in the gonadally intact vehicle group were 15.0  7.0 pg/ml, 
with a range of 4.7-23.1 pg/ml. Levels of E2 in non-E2 OVX treatment groups were 
undetectable.  
Serum LH levels: 
The mean serum LH levels are summarized in Table 1. ANOVA revealed a significant 
effect of Treatment (F(5,61)=14.9, p < 0.01), and post-hoc analysis revealed vehicle, G-1, DPN, 
and PPT treatment groups differed significantly from intact and estradiol groups.  
Table 1. Effects of Treatment on LH levels. 
Treatment  Mean LH Levels ± SEM 
Intact 0.96 ± 0.85 
OVX+E2 0.25 ± 1.02 
OVX 8.45 ± 0.88 
OVX+G-1 10.16 ± 0.99 
OVX+DPN 9.08 ± 1.04 
OVX+PPT 10.22 ± 0.95 
 
DMP acquisition: 
Results show that ovariectomized (OVX) animals took more days to reach criterion than 
gonadally intact animals, and that E2 and all three selective estrogen receptor agonists were able 
to restore the rate of acquisition to that of gonadally intact controls (Fig. 1). On average, OVX 
controls took 13±0.59 days to learn the task. All other groups took an average of approximately 9 
to 10 days to reach criterion on the task. ANOVA revealed a significant effect of Treatment 
(F(5,62)=6.60, p < 0.01). Post-hoc analysis revealed that E2 treatment and all selective estrogen 
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receptor agonist treatments differed significantly from OVX controls. E2 and selective estrogen 
receptor agonist treatments did not significantly differ from gonadally intact controls. There was 
no significant correlation between DTC and circulating E2 levels in the E2-treated or intact 
groups.  Likewise there was no significant correlation between DTC and serum LH levels in any 
of the treatment groups. 
 
Figure 16. Bar graph summarizing Days to Criterion (DTC) for each treatment group 
(Hammond et al., 2009). Bars indicate mean number of days  SEM. *p < 0.05 relative to OVX 
vehicle. 
Examination of the learning curves revealed that all groups performed similarly below 
chance at the start of training (no effect of treatment on Block 1), and that rats receiving E2 or 
agonist treatments acquired the task at a faster rate than the vehicle group (Fig. 2). ANOVA 
revealed a significant effect of Treatment (F(5,62)= 5.74, p < 0.01), a significant effect of Block 
(F(3,60)= 94.4, p < 0.01), and a significant Treatment x Block interaction (F15,166)=1.88, 
p<0.028). Post-hoc analysis of the main effects of treatments collapsed across Blocks 2-5 
revealed significant differences between OVX controls and intact (p<0.01), E2 (p<0.0041), G-1 
(p<0.01), PPT (p<0.0025), and DPN (p<0.01) treatments. Significance was adjusted to p ≤ 0.01 
to account for multiple comparisons. One way ANOVA for each block followed by a post-hoc 
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Tukey test showed that the intact group was significantly different from OVX controls at Blocks 
2-3, and that the G-1 treatment group was significantly different from OVX controls at Blocks 2-
4.  
 
Figure 17. Learning curves showing acquisition of the DMP task over time (Hammond et al., 
2009). Values represent the mean percent correct  SEM within a 3-day block of training for 
each treatment group. *p < 0.05 for intact group relative to OVX vehicle. p < 0.05 for G-1 
treatment relative  to OVX vehicle. 
 
Previous studies show that some rats will adopt a persistent turn early on during testing 
and that this can affect DTC (Gibbs, 2007; Gibbs and Johnson, 2007). To quantify this, we 
examined whether rats adopted a persistent turn, defined as entering the same arm at least 15/16 
times during the choice trial over two days. Results show that a minority (26%) of rats adopted a 
persistent turn (consistently entering either arm of the maze). Treatments had no affect on the 
percentage of rats that adopted a persistent turn (X2 (5)=2.9, p=0.71). Among rats that did adopt a 
persistent turn, treatments did not affect the number of days that this pattern persisted 
(F(5,17)=1.3, p=0.32). 
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Post-criterion Testing: 
After reaching criterion, rotating the maze 180° between the forced and open choices 
significantly disrupted performance within most groups. Performance dropped from 93.8% 
(criterion level) as a result of rotating the maze 180˚ between the forced and open trials (Table 
2). Analysis showed that none of these values differed significantly from chance with the 
exception of the PPT-treated group, which scored significantly above chance (X2=9.7, p<0.02). 
Nevertheless, no significant overall effect of Treatment on performance during the probe trial 
was detected (X2=5.9, p > 0.4).  
Table 2. Effect of Treatment on Performance of 180°-Rotated Maze 
Treatment Performance on Rotated Maze 
Intact 60% 
OVX+E2 44.4% 
OVX 53.3% 
OVX+G-1 72.7% 
OVX+DPN 72.7% 
OVX+PPT 83.3% 
 
 Once rats had reached criterion, increasing the intertrial delay impaired performance for 
all treatment groups (Fig. 3). ANOVA revealed a significant effect of Delay (F(3,60)=8.9, p < 
0.01), no significant effect of Treatment (F(5,62)=0.7, p > 0.6), and no significant interaction 
between Treatment and Delay (F(15,166)=1.15, p > 0.3). 
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Figure 18. Effects of increasing the delay between the forced and open trials to 30, 60, and 90 
seconds on DMP performance (Hammond et al., 2009). Bars represent the percentage of correct 
choices  SEM for each group. 
 iv. Discussion 
 Effects of E2 and ER agonists on DMP acquisition 
 Our results confirm that OVX slowed the rate of DMP acquisition in young adults rats, 
and that PPT, DPN, G-1, and E2 each were able to restore the rate of DMP acquisition to that of 
gonadally intact controls. This is consistent with previous studies showing that E2 enhances 
DMP acquisition in young rats (Gibbs, 1999; Gibbs, 2007), and suggests that activity at any of 
the three established ERs might underlie this effect. Moreover, similar performance was 
observed in intact cycling rats and OVX rats with sustained E2 replacement. Although we did 
not monitor cycles, we assume that the intact rats were undergoing estrous cycles. The fact that 
E2 levels were low in some of these rats suggests that they were killed on diestrus, whereas 
others were killed at other phases of the cycle. This suggests that sustained elevated E2 levels are 
not required to enhance acquisition of the DMP task. Controversy exists over whether cyclical or 
sustained E2 treatment is more effective in enhancing cognitive performance (Gresack and Frick, 
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2006b; Iivonen et al., 2006; Rapp et al., 2003). We also note that the effect of E2 on the learning 
curve, though significant, was not as robust as in some previous reports, possibly due to the 
relatively high levels of E2 achieved in the E2 treatment group. Some studies have reported that 
high doses of E2 can impair spatial working memory in rats(Wide et al., 2004). 
 Recent studies suggest that elevated levels of LH that occur in response to ovariectomy 
may contribute to the cognitive impairment associated with ovariectomy, aging, and 
neurodegenerative diseases (Casadesus et al., 2007; Webber et al., 2006). It has been shown that 
intraperitoneal or intracerebroventricular administration of human chorionic gonadotropin 
produces deficits on T-maze tasks in rats (Lukacs et al., 1995), and that increased LH levels in 
mice are associated with declines in cognitive performance on a Y-maze task (Casadesus et al., 
2007). In the present study, we detected no correlation between LH levels and the number of 
days required to reach criterion on the task in any of the treatment groups.  In addition, G-1, 
DPN, and PPT all significantly enhanced the rate of DMP acquisition despite the fact that LH 
levels were very high relative to intact and E-treated groups.  This suggests that the effects of 
ovariectomy and estrogen treatments on the rate of DMP acquisition are not due to effects of LH. 
Treatment Effects on Learning Strategy and Working Memory 
 Rats can use various strategies to solve T-maze tasks, such as place strategies, which use 
extramaze visual cues, and response strategies, which use body positioning and kinetic cues 
(Dudchenko, 2001b; Korol et al., 2004). Rats also have been shown to change strategy with 
repeated testing or in response to estradiol treatment (Korol and Kolo, 2002; Packard and 
McGaugh, 1996). Evidence suggests place learning is mediated by hippocampal circuits 
(Zurkovsky et al., 2006) while response learning is mediated by extrapyramidal circuits, such as 
through the caudate (Packard and McGaugh, 1996; Squire, 1998). Moreover, place learning is 
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acquired faster than response learning (Chang and Gold, 2003; Packard and McGaugh, 1996). 
Results of the probe trial suggest that upon reaching criterion most treatment groups used 
extramaze cues to a significant degree while performing the DMP task. PPT-treated rats were 
slightly less affected by rotating the maze than the other groups, which may indicate a slightly 
greater predisposition to use a response vs. a place-based strategy; however, this difference was 
not statistically significant.  In addition, treatments had no effect on the predisposition to adopt a 
persistent turn.  This suggests that the effects of the selective ER agonists on DMP acquisition 
were not due to differential effects on strategy.  The hippocampus also plays an important role in 
spatial working memory.  Results of the delay trials indicate that the effects of the selective ER 
agonists on DMP acquisition cannot be accounted for by effects on spatial working memory. 
These findings are consistent with a recent analysis of the effects of E2 on DMP acquisition in 
young rats (Gibbs, 2007). 
Comparison with Previous Studies 
This study showed that chronic E2 treatment throughout training and testing enhanced 
acquisition of the DMP task. Others have used a post-training regimen and have shown that E2 
can be administered in the period immediately after training to enhance performance. For 
example, OVX rats that were trained in a hidden platform water maze and given E2 injections 
less than two hours post training performed better than vehicle controls when returned to the 
maze 24 hours later for a retention test. This enhancement in retention did not occur when E2 
was given later than two hours post training (Packard, 1998). In another case, OVX rats were 
trained in an inhibitory avoidance task and tested following a 24 hour delay, and it was shown 
that E2 administration immediately, but not 1, 2, or 3 hours post training, increased crossover 
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latencies compared to vehicle (Rhodes and Frye, 2004).  Taken together, these suggest that E2 
may affect both acquisition and memory consolidation. 
In addition to spatial learning and memory, others have examined the effects of DPN and 
PPT on stress and anxiety. Daily treatment with DPN has been shown to decrease anxiety-related 
behaviors on tasks such as the elevated plus maze or open field, suggesting that ERß mediates 
select anxiolytic effects of E2 (Lund et al., 2005; Walf and Frye, 2005).  In contrast, daily 
injections of PPT have been reported to increase anxiogenic behaviors such as the number of 
fecal boli and time spent grooming (Lund et al., 2005). Thus, it is important when analyzing 
effects of PPT and DPN on learning tasks to consider the degree to which stress and anxiety play 
a role in each task.   Though we did not measure corticosterone levels, to our knowledge stress 
and anxiety are not major components of the DMP task, analogous to other food-motivated land-
based navigational tasks. While rats do experience the stress of food deprivation, the task does 
not include an acute stressor such as foot shock or swimming, which are major components of 
standard inhibitory avoidance and water maze tasks. 
The parallel effect of the three agonists in facilitating acquisition raises the possibility 
that E2 and the three agonists may affect non-mnemonic processes such as sensory-motor 
functions, motivational factors, or attentional mechanisms. Previous work from our lab has 
shown that OVX and E2 treatments that affect DMP acquisition have no effect on a configural 
association operant conditioning task (Gibbs and Gabor, 2003).  This task requires rats to 
distinguish between visual and auditory stimuli and is motivated by the same food reward 
associated with the DMP task.  The fact that OVX and E2 treatments have no effect on this task 
reduces the likelihood that effects on motivation and sensory perception underlie the effects on 
DMP acquisition. 
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What circuits underlie the effects of the selective estrogen receptor agonists on DMP 
acquisition is unknown. As mentioned earlier, ER  immunoreactivity and mRNA have been 
found in the hippocampus, and ER  immunoreactivity and mRNA have been found in the 
hippocampus and neocortex (Mitra et al., 2003; Osterlund et al., 1998). This raises the possibility 
that DPN and PPT may act directly at one of these two regions to affect DMP acquisition.  
This is the first study to show an effect of G-1 administration on a cognitive task. Results 
show that G-1 had as much of a beneficial effect on DMP acquisition as any of the other 
agonists, suggesting that activation of GPR30 is a viable strategy for enhancing performance 
within specific cognitive domains. 
2.  Effects of G-15, a GPR30 Antagonist 
i. Overview 
The previous section showed that administration of G-1 to OVX rats enhances acquisition 
of a delayed matching-to-position (DMP) T-maze task similar to E2. The next goal was to 
evaluate the effects of a selective GPR30 antagonist (G-15) administered to gonadally intact rats, 
and to OVX rats treated with or without E2. We hypothesized that use of a GPR30 antagonist 
would impair the ability of E2 to enhance spatial learning. Rats were chronically administered G-
15 at 5, 10, or 40 g/day and tested on DMP T-maze as already described. 
ii. Methods 
A total of 75 3-4 month old female Sprague-Dawley rats were used Two weeks prior to 
treatments and testing, rats were handled daily for 5 minutes, food restricted, and maintained at 
85% of normal body weight during acquisition and testing on both tasks. 2-3 weeks following 
ovariectomy rats were given drug treatments. Rats were administered G-15 (a gift from Eric 
Prossnitz, University of New Mexico, also purchased from Calbiochem, Inc.; La Jolla, CA) or 
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vehicle by Alzet model 2006 mini-osmotic pumps implanted s.c. in the dorsal neck region. The 
pumps delivered a volume of 0.15 l per hour over 42 days. G-15 was administered at a rate of 
5, 10, or 40 g/day in a vehicle of 33.7% DMSO + 20% hydroxypropyl- -cyclodextrin 
(HP CD). Doses were selected based on our previous work showing that 5 g/day of the 
selective GPR30 agonist G-1 enhanced learning on the DMP task similar to estradiol (Hammond 
et al., 2009). Rats receiving E2 received 3-mm silastic capsules (length 5 mm; inner diameter 
1.47 mm) implanted s.c. in the dorsal neck region. The E2 capsules produce levels of E2 in the 
physiological range for up to 2 months post-implantation. These levels have been shown to 
enhance DMP acquisition in young adult OVX female rats (Gibbs, 1999; Gibbs, 2002; Gibbs et 
al., 2004). One week following implantation of pumps and/or capsules rats began T-maze 
training. 
Following training, rats were given an overdose of ketamine (40 mg/kg) and xylazine (28 
mg/kg) injected i.p. and euthanized by decapitation. Trunk blood was collected for the 
determination of serum estradiol levels, which were determined using a sensitive LC-MS/MS 
assay recently developed by the Small Molecules Biomolecular Core Facility in our Department 
of Pharmaceutical Sciences. Samples were spiked with internal standard (2,4,16,16,17-d3-17ß-
estradiol) and then extracted with n-butyl chloride. After centrifugation and evaporation, the 
residue was derivatized in 0.1 mL buffered dansyl chloride solution (pH 10.5). E2 was eluted 
from a Waters Acquity UPLC BEH C18, 1.7 um, 2.1 × 150 mm reversed-phase column, with an 
acetonitrile:water (0.1% formic acid) gradient. Detection and quantitation were achieved in the 
positive mode with a Thermo Fisher TSQ Quantum Ultra mass spectrometer interfaced via an 
electrospray ionization (ESI) probe with the Waters UPLC Acquity solvent delivery system. 
Transitions used for analysis were 506 → 171 for E2, and 511 → 171 for the deuterated internal 
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standard. Area under the peak was quantified and used to determine absolute levels of E2/mL of 
sample by comparison with a series of standards. The limit of detectability for this assay is 2.5 
pg/mL. Intra-assay statistics show errors below 8.1% and relative standard deviations below 
10.4%. Inter-assay statistics show errors below 5.0% with relative standard deviations below 
7.4%. 
Rats were tested in the T-maze as described in the previous chapter. 
Partway through the study we realized that E2 levels in many of the gonadally intact rats 
were relatively low.  This was likely due to the fact that rats were euthanized randomly at 
different points along the estrous cycle.  Nevertheless, we thought it best to test any potential 
effect of G-15 on the estrous cycle and on levels of E2.  A separate cohort of gonadally intact 
rats were treated with G-15 (40 µg/day) or vehicle for a period of four weeks. Daily vaginal 
smears were collected beginning several days following the initiation of treatment.  Smears were 
stained with cresyl violet and analyzed to determine cycle stage.  After four weeks of treatment, 
rats were euthanized and plasma was collected and analyzed to determine serum levels of E2 as 
described above. 
iii. Results 
Serum estradiol levels: 
Mean levels of E2 in the gonadally intact rats are summarized in Table 3. Levels in many rats 
were below detectability and were assigned values of 0 for the purpose of calculating averages.  
However, these low values are not unexpected given that rats were euthanized randomly with 
respect to the estrous cycle.  Group differences were not statistically significant. E2 levels for all 
OVX rats were undetectable. Levels in the OVX+E2 group were 50.7  1.52 pg/ml, with a range 
of 32.32 – 75.28 pg/ml. Levels in the OVX+E2+G-15 group were 49.56  1.47 pg/ml, with a 
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range of 34.52 – 77.31 pg/ml.  These levels are consistent with the reported peak levels obtained 
on the afternoon of proestrus (McGinnis et al., 1981). In the separate cohort of rats whose cycles 
were monitored, mean levels of E2 were 5.05  4.40 pg/ml and 9.60  5.17 pg/ml for vehicle- 
and G-15-treated rats.  These differences were not statistically significant.  Again, levels were 
undetectable in some rats, consistent with the fact that some rats were sacrificed during diestrus 
or metestrus.  
 
Table 3. Effects of Treatment on Serum E2 Levels 
Treatment Serum E2 Levels ± SEM 
Intact 4.6  0.65 pg/ml 
OVX+G-15 (5 µg/day) 1.9 ± 0.14 pg/ml 
OVX+G-15 (10 µg/day) 2.32 ± 0.34 pg/ml 
 
Analysis of the vaginal smears indicated that all rats in both the vehicle and the G-15-
treated groups experienced estrous cycles of 4-5 days in length. Cycle stage was determined by 
classifying the epithelial cells into parabasal, intermediate, or superficial cells. Parabasal cells are 
the smallest cells seen in a smear and are prevalent during diestrus, anestrus, and early proestrus, 
but absent during estrus. Intermediate cells are typically 2-3 times the size of parabasal cells and 
are seen during all stages except estrus. Superficial cells are the largest cells with polygonal 
shapes and pyknotic or absent nuclei. They are the defining cell type during estrus. Examples of 
these cell types are shown in Figure 13. 
 55 
 
Figure 19. Examples of typical epithelial cell types seen in vaginal smears (Bowen, 1998). A. 
Arrows point to parabasal cells. B. Arrow points to a large intermediate cell. C. Examples of two 
superficial cells. The left cell has a pyknotic nuclei and the right has none (these cells are 
sometimes referred to as fully cornified).  
 DMP T-maze acquisition: 
G-15 dose-dependently impaired performance in gonadally intact rats (Figure 1). 
Gonadally intact rats treated with 10 g/day of G-15 required significantly more days on average 
to reach criterion (13.3 ±0.9 days for rats treated with 10 µg/day G-15) than vehicle treated intact 
controls (10.0 ± 0.3 days) and performed similarly to OVX controls. ANOVA revealed a 
significant effect of Treatment (F(2,23)=7.66, p < 0.01). Post-hoc analysis revealed that in intact 
rats treated with G-15 at a dose of 10 g/day differed significantly from gonadally intact 
controls. 
 56 
G-15 dose-dependently impaired performance in OVX+E2-treated rats (Figure 1). OVX 
rats treated with E2 + 40 g/day G-15 required significantly more days to reach criterion (14.0 ± 
0.9) than OVX rats treated with E2 alone (9.2 ± 0.6).  ANOVA revealed a significant effect of 
Treatment (F(4,44)=5.64, p < 0.01). Among OVX rats, those treated with E2 learned 
significantly faster than OVX controls, and OVX+E2+G-15 (40 g/day) rats took significantly 
longer than OVX+E2 rats (p<0.05 in each case). Rats treated with G-15 alone did not differ 
significantly from OVX controls but differed significantly from OVX+E2-treated rats. 
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Figure 20. Effects of G-15 on DTC in gonadally intact rats and in OVX rats. 1A shows G-15 
dose-dependently increased DTC in gonadally intact rats, similar to the effects of OVX.   1B 
shows E2 treatment significantly decreased DTC in OVX rats and this was dose-dependently 
reversed by G-15.  G-15 alone had no significant effect on DTC in OVX rats. Bars indicate mean 
number of days to react criterion  s.e.m. *p  0.05 relative to gonadally intact controls or 
OVX+E2-treated rats. # p  0.05 relative to OVX vehicle controls. 
 
Learning curves show that all groups performed similarly below chance at the start of 
training and then improved at different rates. Among the gonadally intact rats, controls acquired 
the task at a significantly faster rate than those that recevied G-15 at 10 g/day (Figure 2A). In 
analyzing Blocks 3-5, ANOVA revealed a significant effect of Treatment (F(2,23)=3.43, p < 
0.05) and a significant effect of Block (F(2,22)= 18.5, p < 0.01). Post-hoc analysis revealed 
significant differences between the controls and the G-15 (10 g/day) group (p < 0.01) on Block 
4. 
Among OVX rats, those treated with E2 acquired the task at a significantly faster rate 
than all other OVX groups (Figure 2B). OVX controls did not differ significantly from any of the 
G-15-treated groups. In analyzing Blocks 3-5 ANOVA revealed a significant effect of Treatment 
(F(4,44)= 4.83, p < 0.01) a significant effect of Block (F(2,43)= 44.2, p < 0.01), and a significant 
Treatment x Block interaction (F(8,86)=2.1, p < 0.05). Post-hoc analysis revealed significant 
differences between the OVX+E2 group and the OVX+G-15 (40 g/day) group and 
OVX+E2+G-15 (40 g/day) group on Blocks 3 and 4. 
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Figure 21. Learning curves showing acquisition of the DMP task over time. Values represent the 
mean percent correct  s.e.m. within a 3-day block of training for each treatment group. Panel 
2A shows learning curves for all gonadally intact rats. *p  0.05 for G-15 (10 g/day) relative to 
intact vehicles. Panel 2B shows learning curves for all OVX rats. *p  0.05 for OVX+G-15 (40 
g/day) and OVX+E2+G-15(40 g/day) relative to OVX+E2-treated rats.  
 
Previous studies show that some rats adopt a persistent turn early on during DMP training 
and that this can affect DTC (Gibbs, 2007; Gibbs and Johnson, 2007). To quantify this, we 
examined whether rats adopted a persistent turn, defined as entering the same arm at least 15/16 
times during the choice trial over a two day period. Results show that ovariectomy significantly 
increased the percentage of rats that adopted a persistent turn (28.6% of gonadally intact controls 
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vs. 83.3% of OVX controls). Treatments also affected the percentage of rats that adopted a 
persistent turn.  Among gonadally intact rats, G-15 dose-dependently increased the percentage of 
rats that adopted a persistent turn  (X2=6.9, p < 0.05) as well as the average numbers of days that 
rats engaged in a persistent turn (Table 1).  Among OVX rats, E2 significantly decreased the 
percentage of rats that adopted a persistent turn and decreased the average number of days that 
rats engaged in a persistent turn. However, G-15 at the highest dose blocked this effect.  G-15 
alone had no effect on persistent turn on OVX rats (X2=23.1, p < 0.01, Table 1). 
 
 
Post-criterion Testing: 
After reaching criterion, rotating the maze 180° between the forced and open choices 
significantly disrupted performance within most groups. Performance dropped from 93.8% 
(criterion level) to 42% for intact groups and to 49% for all OVX groups as a result of rotating 
the maze 180˚ between the forced and open trials. Analysis showed no significant effects of 
Treatment on performance during the probe trial (X2=0.95, p > 0.6 for intact groups; X2=2.1, p > 
0.7 for OVX groups), suggesting that treatments did not differentially affect the degree to which 
rats relied upon extramaze cues to solve the task.  
Table 1:  Effects of Treatments on Adoption of a Persistent Turn During DMP Training 
Group Percentage that 
Adopted 
a Persistent Turn 
Average Length of 
Persistent Turn (Days ± 
s.e.m.) 
Intact Vehicle Controls 28.6 0.6 ± 0.4† 
Intact+G15 (5ug/day) 50.0 2.0 ± 0.8 
Intact+G15 (10ug/day) 88.9* 3.6 ± 0.7* 
   
OVX Vehicle Controls 83.3* 4.1 ± 0.6* 
OVX+G15 (40ug/day) 88.9* 3.4 ± 0.6 
OVX+E2 33.3† 2.0 ± 0.3† 
OVX+E2+G15 (10ug/day) 11.1† 2.0 ± 0.2† 
OVX+E2+G15 (40ug/day) 90.0* 5.4 ± 1.2* 
*p<0.05 relative to Intact Vehicle controls; †p<0.05 relative to OVX Vehicle Controls 
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During post-criterion testing, increasing the intertrial delay impaired performance for all 
treatment groups (Figure 3). Treatments did not differentially alter this effect. For gonadally 
intact rats, ANOVA revealed a significant effect of Delay (F(3,21)=5.7, p < 0.01),  no significant 
effect of Treatment (F(2,23)=0.11, p > 0.3) and no significant interaction between Treatment and 
Delay (F(6,42)=0.71, p > 0.3).  For OVX groups, ANOVA revealed a significant effect of Delay 
(F(3,42)=13.4, p < 0.01), no significant effect of Treatment (F(4,44)=0.46, p > 0.8), and no 
significant interaction between Treatment and Delay (F(12,111)=0.77, p > 0.5). 
  
Figure 22. Bar graphs showing effects of increasing the delay between the forced and open trials 
to 30, 60, and 90 seconds on performance. Bars represent the percentage of correct choices  
s.e.m. for each group.  Panel A shows results for gonadally intact rats.  Panel B shows results for 
OVX rats. 
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iv. Discussion 
Effects of E2 and G-15 on DMP acquisition 
Our findings corroborate previous work showing that ovariectomy slows the rate of DMP 
acquisition in young adult rats, and that E2 can restore the rate of DMP acquisition to that of 
gonadally intact controls (Gibbs, 1999; Gibbs, 2007). The present study showed that G-15 dose-
dependently impaired acquisition in gonadally intact rats and blocked the effect of E2 on DMP 
acquisition in OVX rats. Rats treated with the higher doses of G-15 performed comparable to 
OVX controls.  Notably, the dose required to block the effect of E2 in OVX rats was higher than 
that needed to affect performance in gonadally intact controls, possibly because OVX+E2-treated 
rats had sustained elevated levels of E2 in the high physiological range. 
G-15 at the dose used had no apparent effect on DMP acquisition in OVX rats, 
suggesting that results were not due to a non-specific effect of G-15 on performance. Recent 
work from Smejkalova et al. suggests that E2 synthesized in the brain may be important for 
neural plasticity in the hippocampus (Smejkalova and Woolley, 2010). The finding that G15 fails 
to influence learning or working memory in OVX rats also suggests that local release of E2 and 
subsequent signaling through non-nuclear means does not play a substantial role in the observed 
effects of E2 treatment on this task. Moreover, there were no treatment effects on delay-
dependent performance once rats had reached criterion. This is consistent with previously 
published work from our lab showing that E2 enhances the rate of acquisition but not 
performance during increasing intertrial delays (Gibbs et al., 2004; Gibbs, 2007).  These finding 
are consistent with the hypothesis that the effects of E2 on DMP acquisition are task-specific and 
may be mediated, at least in part, via GPR30.  
Effects of treatments on learning strategy 
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Rats use various strategies to solve T-maze tasks such as place strategies (use of 
extramaze visual cues) and response strategies (use body positioning and kinetic cues) 
(Dudchenko, 2001a; Korol et al., 2004). Strategy choice is hormone-sensitive, as Korol et al. 
showed changes in learning strategies from place to response across the estrous cycle (Korol et 
al., 2004), and others have shown that acute and chronic E2 treatment biases rats towards place 
strategies (Daniel and Lee, 2004; Davis et al., 2005; Korol and Kolo, 2002). Results from the 
probe trial suggest that while rats in each treatment group used both strategies to solve the task, 
there was a trend for intact and E2-treated rats to use place strategies and OVX or G-15 treated 
rats to use response strategies. 
Effects of G-15 were not due to effects on estrous cycles or ovarian function 
E2 levels in the gonadally intact rats were low.  This can be explained by the fact that rats 
were killed randomly with respect to the estrous cycle. Nevertheless, we considered the 
possibility that G-15 might affect performance by interfering with ovarian function. In a separate 
cohort of rats, we observed no effect of sustained G-15 delivery on estrous cycles or on serum 
levels of E2.  This is consistent with the fact that in mice, knock-out of the GPR30 gene does not 
impair normal reproduction (Otto et al., 2009a). This suggests that the effects of G-15 on DMP 
acquisition in gonadally intact rats were not due to an effect on ovarian function or on circulating 
levels of E2.  
Effects on persistent turn and relevance to basal forebrain cholinergic neurons 
Results also show that gonadally intact rats treated with G-15, and OVX+E2-treated rats 
that received G-15, were more likely to adopt a persistent turn during DMP acquisition than rats 
that did not receive G-15. In fact, in cycling rats 8 out of 9 rats receiving 10 g/day of G-15 
adopted a persistent turn, in comparison with only 2 out of 7 vehicle treated controls. G-15 also 
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increased the average number of days that rats engaged in a persistent turn. The same trend was 
observed in the OVX+E2 rats treated with the highest dose of G-15. This suggests that G-15 
impairs performance on this task by increasing the predisposition to adopt and maintain a 
persistent turn. Notably, these same effects are produced by basal forebrain cholinergic lesions 
(Gibbs and Johnson, 2007), suggesting that both G-15 and lesions affect response pattern, 
strategy selection, and the ability to alter strategy (i.e., cognitive flexibility) in a similar way. 
As mentioned above, cholinergic neurons in the medial septum and nucleus basalis 
magnocellularis are the primary source of cholinergic inputs to the hippocampus and cortex and 
play an important role in learning, memory, and attentional processes (Baxter and Chiba, 1999; 
Everitt and Robbins, 1997; Gritti et al., 1997; Mesulam, 1996). Studies show that selectively 
lesioning these cells produces an increase in the predisposition to adopt a persistent turn during 
DMP acquisition (Gibbs, 2002; Gibbs, 2007).  A similar effect is observed in aged rats and can 
be reversed, in part, by treating with selective cholinesterase inhibitors (Bohacek et al., 2008; 
Gibbs et al., 2009) (Gibbs et al., 2011a; Gibbs et al., 2011b).  This suggests that cholinergic 
inputs to the hippocampus and cortex have a strong effect on perseveration and the adoption of a 
persistent turn during DMP training.  Prior studies show that E2 has a number of effects on basal 
forebrain cholinergic neurons including increasing choline acetyltransferase mRNA and protein 
(Gibbs et al., 1997; Gibbs, 2000; Singh et al., 1994), increasing high affinity choline uptake in 
the hippocampus and frontal cortex (O'Malley et al., 1987; Tinkler et al., 2004), and increasing 
potassium-stimulated acetylcholine release (Gabor et al., 2003; Gibbs, 1997).   In addition, we 
have shown that septal cholinergic neurons are essential for E2-mediated enhancement of DMP 
acquisition (Gibbs, 2002).  Recently we showed that cholinergic neurons in the medial septum 
and nucleus basalis magnocellularis also contain GPR30, and that G-1, a selective GPR30 
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agonist, enhances potassium-stimulated acetylcholine release in the hippocampus similar to E2 
(Hammond et al., 2010).  Collectively, these data suggest that E2 can enhance basal forebrain 
cholinergic function via GPR30, and support the hypothesis that the effects of G-15 on DMP 
acquisition are due, at least in part, to a blockade of E2 effects on basal forebrain cholinergic 
neurons.  Future studies will focus on testing this hypothesis. Specifically, studies looking at G-
15 effects on the ability of E2 to enhance potassium-stimulated acetylcholine release or to 
enhance choline acetyl transferase activity will help further test this hypothesis. 
 
B. OPERANT CONDITIONING  
i. Overview 
As was discussed in the introduction, E2 enhances learning in a task-specific manner. 
Previous work from our lab has shown that E2 does not enhance learning in operant conditioning 
tasks (Gibbs et al., 2011a). We examined the effects of G-15 on a non-spatial learning task. A 
subset of rats that were chronically administered G-15 at 5 or 10 g/day and completed the DMP 
T-maze task were next tested in a successive conditional discrimination (SCD) task.  We 
hypothesized that, like E2, G-1 would only enhance learning on the spatial (T-maze) task. 
ii. Methods 
Upon completion of the DMP T-maze task rats were trained on the SCD task. Training 
was performed in operant chambers (Med. Associates, Inc., Georgia, VT) connected to a 
computer running Med-PC software. Each operant chamber contained a dim red house light, a 
ventilation fan, a 6 W stimulus panel light, a speaker calibrated to present a 1500 Hz tone, a 
pellet dispenser, and a recessed food cup located immediately below the panel light. Entry into 
the food cup was monitored by a photosensor. Rats were adapted to the chamber by receiving 
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one 60 min session during which they received a total of 16 food pellets delivered at intervals 
ranging from 2 to 6 min. Testing began the following day. Each rat received one training session 
per day for a total of 14 days. During the session, rats received 30 presentations of a tone 
stimulus and 30 presentations of a light stimulus. Rats were randomly divided into 2 groups and 
trained to respond to only one of the stimuli (either tone or light), which will be referred to as the 
reinforced stimuli. If the rat entered the food cup within 10 sec of the presentation of the 
reinforced stimuli, the stimulus discontinued and the animal received a food reward (one 45 mg 
pellet). If an animal entered the food cup during the non-reinforced stimulus, the stimulus was 
discontinued, the house light turned off for 60 sec, and no food was delivered. This is referred to 
as a time out. The stimuli presentations were randomly distributed throughout the session and 
occurred at one of 30 randomly selected intertrial intervals ranging from 12 to 70 sec. After 6 
days of testing, testing was reversed and rats had to learn to respond to the initially non-
reinforced stimulus in order to receive a food reward. Reversal learning was tested for 8 days. 
Following training, animals were given an overdose of ketamine (40 mg/kg) and xylazine 
(28 mg/kg) injected i.p. and euthanized by decapitation. Trunk blood was collected for the 
determination of serum estradiol levels. For estradiol analysis, samples were extracted with ether 
and resuspended in buffer. Samples were then analyzed in duplicate by RIA using a kit from 
Diagnostic Systems Laboratories, Inc. (Webster, TX). The estradiol assay was performed by the 
assay core of the Center for Reproductive Physiology at the University of Pittsburgh. 
iii. Results  
In contrast to effects on DMP acquisition, neither OVX nor E2 treatment had any 
significant effect on OD/RL performance.  Likewise, G-15 treatment had no effect on OD/RL 
acquisition or reversal learning in gonadally intact rats (Figure 16). ANOVA revealed no 
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significant effect of Treatment on number of correct choices (F(3,29)= 0.95, p > 0.4) (Figure 4A) 
or incorrect choices (F(3,29)= 0.51, p > 0.7) (Figure 4B) during the acquisition or reversal 
learning phases.  
 
Figure 23. Learning curves showing number of correct choices (A) and number of incorrect 
choices (B) made by rats during successive choice discrimination. Rats were trained to respond 
to either light or sound for the first six days and then trained to respond to the opposite stimulus 
for the next eight days. The arrow indicates the day on which the stimulus contingency was 
reversed. 
iv. Discussion 
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In contrast to effects on the DMP task, no effects of ovariectomy or E2 replacement were 
observed on the OD/RL task.  Likewise, G-15 had no effect on OD/RL learning in gonadally 
intact rats. The OD/RL task is a non-spatial operant learning and memory task. Learning requires 
that rats be able to distinguish visual and auditory cues and to associate individual cues with a 
food reward.  The fact that neither OVX, E2 nor G-15 had any affect on this task suggests that 
treatments did not significantly impact these processes.  In addition, as both the DMP task and 
the OD/RL task utilize the same food reward, this suggests that effects on the DMP task are not 
due to an effect on the motivation for food. Many studies have shown that effects of E2 on 
cognitive performance are task selective.  For example, E2 has been shown to improve 
performance on spatial learning (Daniel et al., 1997; Gibbs, 1999), object placement and 
recognition (Fernandez et al., 2008; Gresack and Frick, 2006a), and fear condition tasks (Jasnow 
et al., 2006), but not on specific reference or working memory tasks (Fader et al., 1999; Galea et 
al., 2001), nor on a configural association operant conditioning task (Gibbs and Gabor, 2003; 
Gibbs et al., 2009). Thus, our results agree with previous work showing that the effects of E2 on 
learning and memory tasks are task-specific, and suggest that the effects of G-15 are due to 
interference with the effects of E2, rather than to non-specific effects on learning and memory 
processes. 
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V. SUMMARY AND CONCLUSIONS 
SUMMARY 
 In conclusion, the data shown support the hypothesis that GPR30 mediates E2 effects on 
the basal forebrain cholinergic system with corresponding beneficial effects on cognitive 
performance. We have shown that GPR30 mRNA and protein are expressed in brain regions 
important for learning and memory. In fact, GPR30 is expressed by the majority of cholinergic 
neurons in the basal forebrain. Using microdialysis, we showed that treatment with a GPR30 
agonist can enhance potassium-stimulated acetylcholine release similar to E2. This suggests that 
GPR30 plays a significant role in mediating effects of E2 on acetylcholine release. In our 
behavioral studies we found that GPR30 agonism restores performance of OVX rats on a spatial 
learning task to that of gonadally intact controls, while antagonism impairs performance in a 
dose-dependent fashion. While we showed that other estrogen receptor agonists can also enhance 
performance on this task, the fact that a GPR30 antagonist could block E2 effects suggests that 
GPR30 is necessary for E2-mediated enhancement of learning. Future endeavors will further 
define the role of GPR30 in mediating E2 effects on cholinergic neurons as well as elsewhere in 
the brain, and on the mechanisms by which GPR30 activation elicits these effects. 
 
LIMITATIONS OF STUDIES PRESENTED 
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Future endeavors will also aim to overcome some of the limitations inherent to the work 
presented here. A limitation of any chemical agonist/antagonist study is the possibility that the 
agonist/antagonist is affecting a different protein than the receptor of interest. Future work could 
use tools such as siRNA to more definitively prove that E2 effects on cholinergic function and 
DMP acquisition are GPR30 mediated. Moreover, we only examined the effects of a couple 
doses of G-1 and G-15. More details about these compounds, such as how easily they get into the 
brain, what levels are required to illicit an agonistic or antagonistic effect, or what is the 
selectivity window for each compound, would prove useful when choosing dosing regimens. A 
limitation of the microdialysis and behavior studies is that while we did measure circulating 
levels of E2, we did not measure levels of G-1 or G-15. Assays are currently being developed to 
be able to measure agonist and antagonist levels in serum samples. While these assays will 
answer questions regarding circulating levels, the question still remains of what circulating levels 
are in the brain. Being able to reliably measure minute quantities in the brain is not a trivial 
matter, so future technologies that permit that level of detection should be investigated.  A 
limitation of the immunostaining studies is that the antibody used was a polyclonal antibody, 
which raises the possibility that it is binding to a similar protein as GPR30. As was mentioned 
earlier, there still exists controversy in the field over GPR30 localization (reviewed in (Langer et 
al., 2010). Future work using monoclonal antibodies or doing in situ hybridization would more 
definitively prove GPR30 localization in different regions. 
The fact that we and others have observed GPR30 expression in many non-cholinergic 
neurons and in other regions that do not contain cholinergic projections suggests that GPR30 
may mediate E2 effects on other systems besides the basal forebrain cholinergic system. For 
example, estrogens are known to regulate the release the hypothalamic hormones necessary in 
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reproduction. Brailoiu et al. showed that G-1 increases intracellular calcium levels in cultured rat 
hypothalamic neurons (Brailoiu et al., 2007). G-1 can inhibit serotonin 5HT1A receptor-
mediated attenuation of oxytocin release (Xu et al., 2009). Noel et al. used GPR30 siRNA to 
show that the rapid excitatory affect of E2 on primate LHRH neurons in vitro is partially 
dependent on GPR30 (Noel et al., 2009). Our work has focused on how GPR30 may mediate E2 
effects on the cholinergic system to enhance learning, but the fact that GPR30 is highly 
expressed in the regions such as the hippocampus and cortex suggests the possibility that E2 can 
directly act on these regions to enhance learning and memory, thereby bypassing the cholinergic 
system. Thus, more work needs to be done to clearly define the role of GPR30 in mediating E2 
effects on these different systems.  
 
HOW GPR30 FITS IN WITH ESTROGEN THERAPY 
As was mentioned in the Introduction, the beneficial effects of estrogen therapy on 
cognitive performance diminish with age and time following loss of ovarian function, and this 
finding has led to the Window of Opportunity hypothesis. Effects of estrogen therapy on 
cognition are due, in part, to the effects on cholinergic afferents innervating the hippocampus and 
cortex, and it has been suggested that the loss of estrogen effects with age and time following 
menopause is due to a substantial reduction in the functionality of these projections. GPR30 is 
expressed in brain regions important for learning memory and attention, is expressed by the 
majority of cholinergic neurons in the basal forebrain, and appears to be an important regulator 
of basal forebrain cholinergic function. Therefore, enhancing cholinergic activity, whether 
indirectly via a GPR30 agonist or acetylcholine esterase inhibitors, or directly via selective 
acetylcholine receptor agonists, could be an effect means of re-opening the window of 
 71 
opportunity and restoring beneficial effects of estrogen therapy on cognition. This is supported 
by a recent study from our lab showing that donepezil, a cholinesterase inhibitor used in treating 
Alzheimer’s disease, was effective at restoring effects of E2 on DMP acquisition in aged rats 
(Gibbs et al., 2009). Similar effects have been observed with donepezil + E2 treatment in young 
rats with cholinergic lesions, as well as with galanthamine, another cholinesterase inhibitor, and 
its ability to enhance E2 effects on DMP acquisition in aged rats (Gibbs et al., 2011a). These 
findings are all consistent with clinical studies showing that postmenopausal women with 
Alzheimer’s disease who received estrogen therapy responded better to tacrine (a cholinesterase 
inhibitor formerly used to treat Alzheimer’s disease), than women not on estrogen therapy 
(Schneider et al., 1996). Therefore, combining estrogen therapy with cholinergic enhancers may 
be an effective strategy for re-opening the window of opportunity. Sustained estrogen therapy, 
however, does carry significant risks and side effects, especially in older women (Grady et al., 
1995; Grady et al., 2000; Ross et al., 2000).  Selective GPR30 agonists such as G-1 may offer 
added benefits by avoiding these adverse side effects. Whether G-1 is effective at enhancing 
cholinergic function and cognition in aged rats and is similar affected by the co-administration of 
cholinesterase inhibitors needs to be evaluated. Thus, GPR30 may be an important target for 
developing new therapies that can enhance or restore estrogen effects on cognition in older 
women. 
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